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Importance: Antidepressant use is increasing worldwide. Contrasting evidence from meta-analyses 
is available on their safety.  
Objective: To grade the evidence across meta-analyses of observational studies assessing the 
association between antidepressants and adverse health outcomes, using an umbrella review 
approach.  
Data Sources: We searched PubMed, Scopus, and PsycINFO, up to April 5, 2019. 
Evidence Review: Only meta-analyses of observational studies with a cohort or case-control study 
design were eligible. Two independent reviewers recorded the data and assessed the methodological 
quality of the selected meta-analyses. Evidence was ranked as convincing, highly suggestive, 
suggestive, weak, and not significant according to established criteria.  
Results: Forty-five eligible meta-analyses describing 120 associations including data from 1012 
individual effect size estimates were included, after scrutinizing 252 potential articles. Seventy-four 
of the 120 associations (61.7%) had a nominally statistically significant effect (p≤0.05) using 
random-effects models. Large heterogeneity (I2>50%) was present (43.3%), while small-study 
effects (14.2%) and excess significance bias (7.5%) were less common. While convincing meta-
analytic evidence emerged from both main and sensitivity analysis for the association between 
antidepressants and risk of suicide attempt/completion in children/adolescents (9.4%, OR=1.92, 
95%CI=1.51-2.44 in adjusted studies, SSRIs only, and in high-quality studies, 3.6% OR=1.88, 
95%CI=1.47-2.40), autism spectrum disorders (ASD) with antidepressants before (0.8%, RR=1.48, 
95%CI=1.29-1.71 in any antidepressant, adjusted studies, and high-quality studies) and during 
pregnancy (0.9%, OR=1.84, 95%CI=1.60-2.11 in both high-quality studies and SSRIs only, and 
0.1% OR=1.80, 95%CI=1.54-2.10 in European studies), pre-term birth in prospective cohort studies 
(0.4%, RR=1.87, 95%CI=1.52-2.30), and in studies of mixed antidepressants (0.4%, RR=1.59, 
95%CI=1.31-1.93), and low APGAR scores in SSRIs only studies (5.7%, SMD=-0.27, 95%CI -0.37 
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to -0.16), none of these associations remained at convincing evidence after sensitivity analysis for 
confounding by indication. 
Conclusions and Relevance: Most putative adverse health outcomes associated with antidepressants 
are not supported by convincing evidence, and the few of those supported by convincing evidence 
are affected by confounding by indication. Antidepressants appear to be overall safe for the treatment 
of psychiatric disorders. More studies matching for underlying disease are needed to clarify the 
degree of confounding by indication and other biases. No absolute contraindication to 
antidepressants emerges from this umbrella review. 
Registration: PROSPERO registration 2018: CRD42018103462. 
 


















Key Points  
Question: Are antidepressants associated with adverse health outcomes and how strong is the 
evidence in the published meta-analyses of real-word data? 
Findings:  In this systematic umbrella review of 45 meta-analyses of observational studies, 
convincing evidence was found for the association between antidepressants and suicide 
behavior/completion in individuals aged <19 years old and for autism risk in the offspring. However, 
none of these associations remained at convincing evidence after sensitivity analysis for confounding 
by indication. 
Meaning Claimed adverse health outcomes associated with antidepressants are not supported by 
strong evidence and are exaggerated by confounding by indication. No absolute contraindication to 





Accumulating evidence suggests that there is a sharp growth of antidepressants use worldwide 
(up to 8-10% of American adults take at least one antidepressant - rank third among prescribed and 
fourth among sold medications).1,2 Antidepressants are indicated and used for depressive disorders, 
anxiety disorders, post-traumatic stress disorder, premenstrual dysphoric disorder, obsessive 
compulsive disorder (OCD), binge eating disorder, among others.3-5  
The safety profile of antidepressants is controversial. Since the Food and Drug Administration 
(FDA) introduced the black box warnings associating selective serotonin reuptake inhibitors (SSRIs) 
with an increased risk of suicidal behavior in children and adolescents,6 the debate about efficacy, 
acceptability, and the safety profile of antidepressant medications has gradually increased.7-11 While 
evidence from randomized controlled trials (RCTs) showing antidepressants’ efficacy and 
acceptability has been well documented, in both meta-analyses and network meta-analyses,4,8,10,12,13 
safety assessment is inherently biased by certain methodological weaknesses of RCTs, such as small 
and unrepresentative samples, rare and inconsistent reporting of adverse outcomes, and short 
duration of exposures.14,15  
Observational studies provide complementary evidence to RCTs on a number of adverse health 
outcomes (which may only manifest in the mid- to long-term) utilizing real-world data15 linked to 
antidepressants, which it is not possible in RCTs.16 In particular, observational studies can provide 
useful evidence on medication safety since they are more representative of overall target population, 
for example including patients with comorbid disorders or suicidal thoughts, which are often 
excluded from RCTs. Also, observational studies typically have a longer follow up duration than 
RCTs, providing data on mid- and long-term effects of antidepressants, such as bone status, or 
gastro-intestinal bleeding which may not arise from short-term use.16 Several meta-analyses of 
observational studies assessing antidepressant safety have been published, but no attempt of 
quantifying their credibility has been made to date. The latter is crucial, considering the uncertainty 
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surrounding observational research results.17-19 Umbrella reviews make it feasible to summarize the 
evidence from multiple meta-analyses on the same topic 20,21 and enable a grading (ranking) of 
evidence into convincing, highly suggestive, suggestive, weak, or not significant based on sample 
size, strength of the association, and the assessment of presence of biases.22-24 In this study, we 
graded the evidence from published meta-analyses of observational studies testing the association 
between antidepressant use and risk of adverse health outcomes. 
Methods  
A protocol for this study was registered on PROSPERO 2018: CRD42018103462. We used the 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) recommendations 
25 and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines26 to guide 
this umbrella review.  
Search strategy and selection criteria 
We searched the PubMed, Scopus, and PsycINFO, from inception to April 5, 2019, to identify 
systematic reviews with meta-analysis of observational studies that examined an association between 
any adverse health outcome and exposure to antidepressants. We performed a search strategy using a 
combination of terms related to antidepressants (e.g., ”antidepressants”, “selective serotonin reuptake 
inhibitors”), terms related to adverse health outcomes (e.g., “harms,” “suicide,” “bleeding,” “autism,” 
etc.), and to meta-analysis with no age, sex, population, and medical condition restrictions (for 
details, see eBox1 in the Supplement). We also hand searched the cited references of the retrieved 
articles and reviews.  
Two reviewers (ED, MS) independently searched titles/abstracts for eligibility, and when a 
consensus could not be achieved a third reviewer was consulted (EE). The full-texts of potentially 
eligible articles were retrieved, and the same two investigators independently scrutinized each study 
for eligibility. Any discrepancies were resolved by the third reviewer (EE).  
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We included only peer-reviewed systematic reviews with meta-analysis of observational 
studies with only a cohort, case-control, or nested case-control study design, measuring any 
association between antidepressants and any adverse health outcome in any population of any age. 
Whenever multiple meta-analyses on the same adverse health outcome were performed (i.e., 
overlapping meta-analyses with the same outcome, type of antidepressant, and clinical setting or 
population setting), we assessed only the one that included the largest data set, as previously 
described.22,24,27 Details of the selection between overlapping meta-analyses are described in the 
Supplement. For each eligible meta-analysis, we considered the main analysis for all primary and 
secondary reported outcomes. The concordance between selected and non-selected meta‐analyses 
was examined in a sensitivity analysis.27   
We excluded: 1) meta-analyses of other study designs (e.g., RCTs, cross-sectional) or meta-
analysis included both observational studies and RCTs in the same analysis, 2) published in 
languages other than English, 3) meta-analyses of individual patient or participant data, pooled 
analyses that examined a non-systematic selection of observational studies, and non-systematic 
reviews, 4) meta-analyses of hypericum perforatum, known as perforate St John's-wort, or 
tryptophan, and 5) meta-analyses that provided insufficient or inadequate data for quantitative 
synthesis.  
Data extraction 
Data extraction was performed independently by two investigators (ED, MS) and 
disagreements were resolved by a consensus. Adverse health outcomes related to exposure to 
antidepressants were extracted as defined by the original authors. For each meta-analysis, we 
recorded information on PMID/DOI, first author, publication year, type of antidepressant, study 
design, age of participants, adverse health outcomes, exposure and non-exposure, illnesses examined 
(e.g., depression), the number of included studies, and the total sample size.  
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For each primary study, we recorded information on first author, year of publication, study 
design (i.e., cohort or case-control), number of cases and controls in case-control studies or total 
population in cohort studies, reported adjusted (or unadjusted, if such exists) effect sizes (ESs), i.e.; 
risk ratio (RR); odds ratio (OR), hazard ratio (HR), standardized mean difference (SMD), each with 
their 95% confidence intervals (CIs), and study location. We also captured the number and nature of 
adjustments, length of follow-up, study quality score, and if the studies were controlled for a 
psychiatric condition, i.e., confounding by indication.18,19 
Data were extracted independently by two investigators (ED, MS). The methodological quality 
of each included meta-analysis was assessed with the Assessment of multiple systematic reviews 
(AMSTAR) 2 tool (available at https://amstar.ca/Amstar-2.php), which is a recent update of 
AMSTAR,28 by same two investigators (ED, MS). AMSTAR 2 also accounts for the quality of 
studies included in the meta-analysis, beyond a mere technical methodology assessment of the 
included meta-analysis (for details see supplement).16  
Data analysis 
For each association, we extracted effect sizes of individual studies included in each meta-
analysis, and re-meta-analyzed them calculating the pooled ES and the 95% confidence intervals, 
with random-effects models to compare homogeneously analyzed results.29 We did not transform the 
initial ESs or modify the direction of associations presented by the original authors to compare our 
results with the reported results from the meta-analyses. Heterogeneity was assessed with the I2 
statistic.30 Additionally, we calculated the 95% prediction intervals for the summary random ESs 
providing the possible range in which the ESs of future studies is expected to fall.31  
We then tested whether smaller studies yielded larger ESs than larger ones; an indication of 
small-study effect bias.24,32-34 Small-study effect bias was indicated by both Egger’s regression 
asymmetry test (p≤0.10) and by the random effects’ summary ES being larger than the ES of the 
largest study in each association.24,32-34 Finally, we assessed the existence of excess significance bias 
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by evaluating whether the observed number (O) of studies with nominally statistically significant 
results (“positive” studies, p≤0.05) were different from the expected number (E) of studies with 
statistically significant results.34 The E of statistically significant studies per association was 
calculated by summing the statistical power estimates for each component study. The power 
estimates of each component study depend on the plausible effect size for the tested association, 
which we assumed to be the effect of the largest study (i.e., the smallest standard error) per 
association.35 Excess significance bias was set at p≤0.10. This test is designed to assess whether the 
published meta-analyses comprise an over-representation of false positive findings.34 
Assessment of the credibility of the evidence 
We assessed the credibility of the evidence per association provided in meta-analyses by 
applying several criteria in concordance with previous published umbrella reviews.22,23,32,33,36,37 In 
brief, associations that presented nominally significant random-effects summary ESs (i.e., p≤0.05) 
were ranked as convincing, highly suggestive, suggestive, and weak evidence based on sample size, 
strength of the association, and the assessment of presence of biases (Table 1; for details see 
Supplement). In addition, to provide an estimate of epidemiologic implication of findings, we 
calculated prevalence of outcomes of interest from cohort studies only (studies with case-control 
designs should not be considered for prevalence estimates). 
Sensitivity analysis  
We performed sensitivity analyses to assess whether the credibility of the evidence varied 
within cohort studies (both prospective and retrospective), prospective cohort studies, studies with 
adjustments for multiple covariates, confounding by indication, high-quality studies, classes of 
antidepressants (SSRIs studies, tricyclic antidepressants [TCAs] studies, other or mixed 
antidepressants studies), and study location of the associations ranked as convincing and highly 




We identified 4,471 articles, scrutinized 252 in full text and finally included 45 meta-analyses 
in this umbrella review 38-81 (Figure 1), corresponding to 695 studies, 1012 estimates, and 13 putative 
risks (Figure 2). References of the 207 excluded articles and their reasons are provided in eTable 1.  
Descriptive characteristics of the 45 eligible meta-analyses of observational studies can be 
found in eTable2. All meta-analyses but one had also a control group not exposed to antidepressants, 
in which compared the risk of gastrointestinal (GI) bleeding between mirtazapine and SSRIs.47 The 
median number of adjustments in the analyses was 7 (interquartile range [IQR]=4-11, range 0-31) 
and the median duration of follow-up was 4 years (IQR=2−5).   
Thirty-three meta-analyses (73.4%) met the moderate-quality level according to the 
AMSTAR2 evaluation, and eight (17.8%) were of low quality. Finally, two (4.4%) were high-
quality, while two others (4.4%) were of critically low quality. The two independent investigators 
reached a high level of agreement (91.0%) on the quality rating.   
Description of associations  
Forty-five eligible meta-analyses described 120 associations including 1012 individual study 
estimates of adverse health outcomes related to exposure to antidepressants (see Tables 1 to 2, and 
eTables 3 to 5 in the Supplement), with a median number of estimates per association of 6 (IQR =4-
12). Seventy-four (61.7%) of the associations concerned maternal and pregnancy-related adverse 
health outcomes (Figure 2). Most associations (n=80; 66.7%) concerned SSRIs or SNRIs, nine 
(7.5%) TCAs, and 31 (25.7%) mixed or other antidepressants.  
The median number of the total population per association was 1,056,374 (IQR=152,180 –
2,215,969). The median number of cases (adverse health outcomes) per association was 12,097 
(IQR=2,585−56,272) and the number of cases was >1,000 for 87 associations (72.5%). 
Summary of associations 
A summary of all 120 associations is presented in Tables 2 to 3 and eTables 3 to 5 in the 
Supplement. Seventy-four of the 120 examined associations (61.7%) had a nominally statistically 
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significant effect (p≤0.05) using random-effects models and only 22 of those (18.3%) reached 
p≤1x10-6.Almost all statistically significant associations indicated an increased risk for 
antidepressants and adverse health outcomes, except for two associations showing a protective effect 
of SSRI against suicide attempt/completion in adults and older adults, respectively.80  
Fifty-two associations (43.3%) had large heterogeneity (I2>50%), and only for 24 associations 
(20.0%) the 95% prediction intervals excluded the null value. In 63 associations (52.5%), the ESs of 
the largest study presented a nominally statistically significant effect (p≤0.05). Finally, small-study 
effects were found for 17 associations (14.2%), and excess significance bias was observed for nine 
associations (7.5%).  
Grading of level of evidence of associations 
Main analysis 
Convincing evidence 
Among the 120 associations, three (2.5%) had convincing evidence; the association between 
SSRIs and increased risk of suicide attempt/completion in children and adolescents,80 and the 
association between any antidepressant before pregnancy and SSRIs during pregnancy and autism 
spectrum disorders (ASD)51,52 (Table 2). The association with suicide risk reached high-quality level 
based on AMSTAR2, while the two associations with ASD reached moderate quality.   
Highly suggestive evidence 
For 11 associations (9.2%), there was highly suggestive evidence for the relationship between 
any antidepressant and increased risk of adverse health outcomes (Table 2), namely attention-deficit 
hyperactivity disorder (ADHD) in children, cataract development (TCAs), severe bleeding at any 
site, upper GI bleeding, postpartum hemorrhage, preterm birth, lower APGAR score at 5 minutes, 
osteoporotic fractures (one for TCAs and one for SSRIs), and risk of hip fracture. Seven of these 
associations reached moderate quality level based on AMSTAR2 (Table 2). One association with 
13 
 
highly suggestive evidence, however, showed a decreased risk (i.e., protective association) of suicide 
attempt/completion in adults,80 meeting a high-quality level based on AMSTAR2. 
Suggestive, weak, and no evidence 
There was suggestive evidence for 21 further associations (17.5%) linked to increased risk of 
adverse health outcomes (eTable 3). For the remaining associations, there was either weak (n=39 
[32.5%]) or no evidence (n=46 [38.3%]; all associations with p>0.05) (eTables 4 and 5). 
Sensitivity analyses  
A sensitivity analysis limited to cohort studies, prospective cohort studies, studies controlled 
for confounding by indication, and North American studies showed that none of the associations 
within convincing evidence (class I) retained the same rank (Table 3).The most important change 
was within prospective cohort studies, with one being upgraded to convincing evidence (preterm 
birth related to any antidepressant).  
Another association was upgraded to convincing evidence (lower APGAR scores at 5 minutes) 
when the sensitivity analysis was limited to SSRIs, as well as the association with preterm birth was 
also upgraded to convincing evidence when the analysis was limited to other or mixed 
antidepressants (Table 3).  
A further sensitivity analysis limited to non-selected meta-analyses due to overlap agreed with 
the results of the main analysis (Supplement results and eTable 6). The results of each sensitivity 
analysis are presented in detail in the Supplement with the full list of covariates in eTable 7.  
Discussion   
We reviewed 45 meta-analyses of observational studies and we found that only a few of the 74 
statistically significant associations between antidepressants and adverse health outcomes had 
convincing evidence in main and sensitivity analysis, namely the association between antidepressants 
and increased suicide behavior/completion in individuals aged <19 years old (SSRI),80 autism risk in 
the offspring,51,52 preterm birth,66 and neonatal adaptation.71 However, the few convincing 
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associations do not reflect necessarily causality and, importantly, none of them remained at 
convincing evidence after accounting for confounding by indication. Overall, our results show that 
the association between antidepressants and adverse health outcomes is not supported by robust 
evidence and the underlying disease likely affects the results and inflates significant findings in a 
relevant way.39,44 
To our knowledge, this is the first umbrella review that systematically assesses the potential 
risk of adverse health outcomes related to antidepressants across a large spectrum of published meta-
analyses of observational studies, grading also the evidence by applying well-recognized criteria of 
its credibility. 22,23,32,33,36,37 This umbrella review approach has been previously applied to other fields 
of medicine, such as adverse health outcomes of dietary fiber consumption,37 serum uric acid,23 and 
vitamin D.22 Our approach fits to a research field that is undeniably complex and uncertain, as 
conveyed here. 22,23,32,33,36,37 The large median number of participants and cases per association 
allowed to make robust classifications; the number of cases was greater than 1,000 for 87 out of the 
total of 120 associations. Quality ratings of the included meta-analyses with the AMSTAR2 tool also 
allowed to interpret our results with confidence. Sensitivity analyses provided additional evidence 
from cohort, high-quality studies, and studies that were controlled for a psychiatric condition, further 
increasing reliability of the results.   
Our results need to be considered when contemplating the use of antidepressants in 
children/adolescents integrating this knowledge with data on efficacy from RCTs. A network meta-
analysis of RCTs in children/adolescents showed that no antidepressant was superior to placebo apart 
from fluoxetine, several antidepressants had higher discontinuation rates than placebo, and that 
venlafaxine increased the risk of suicidality even in the short-term duration of an RCT.13 Merging 
lack of efficacy with lack of safety may raise serious concerns on the use of antidepressants in 
children/adolescents, with an unfavorable benefit/risk ratio. However, lack of superiority of 
antidepressants over placebo,12 especially in children, was due to a very high placebo response, 
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which has been an increasing problem in RCTs in psychiatry. Also, it is possible that increased 
suicidality in children/adolescents taking antidepressants may be due to ineffectiveness on depressive 
symptoms in suicidal individuals, rather than to a direct effect of antidepressants. Additionally, our 
results show that confounding by indication probably drives safety concerns on the use of 
antidepressants in children/adolescents. Besides, the risk-benefit evaluation in children and 
adolescents is quite different for antidepressants (predominantly SSRIs) when used for other 
disorders like anxiety disorders and OCD.3-5,12  
Conversely, we found highly suggestive evidence supporting a protective role of 
antidepressants in adults against suicidality,80 which is consistent with results of a network meta-
analysis of RCTs in adults showing that all antidepressants were superior to placebo in reducing 
depressive symptoms.10 Similarly, meta-analyses support the efficacy of antidepressants for anxiety 
disorders 5 and OCD 3 in adults. In adults the benefit/risk ratio must account for clear efficacy of 
antidepressants and protection against suicide, which should be balanced with other safety concerns 
rising from the present umbrella review. Overall, several adverse outcomes associated with 
antidepressants supported by highly suggestive evidence can medically be prevented (i.e., poor bone 
status, gastro-intestinal bleeding) as previously reported.82 Hence, benefits of antidepressants in 
adults and older adults may well trump (preventable) safety issues, given their clear efficacy in 
treating various psychiatric disorders.3-5,12 Moreover, the association between antidepressants and 
certain adverse health outcomes varies within specific age groups. For instance, the increased risk of 
fractures applies predominantly to an older population that is already prone to poor bone status and 
multimorbidity,83 and not in people aged 20-40 years old.  
Convincing evidence before accounting for confounding by indication supporting the 
association between antidepressants and autism, and other offspring adverse health outcomes may 
call for restriction of antidepressants during pregnancy to those women with high risk of relapse and 
with severe clinical presentations. Actually, warnings to avoid prescribing medications in early 
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pregnancy have been already set.84 However, autism remains a rare event, with a prevalence from 
cohort studies of <1% according to data pooled in this study. Importantly, the convincing level of 
evidence was not confirmed when considering confounding by indication, suggesting that the 
association between antidepressants and autism, suicidality in youth, etc. may be due to effects of the 
underlying disease, rather than to antidepressants,39,43,44,50 as recently shown in an umbrella review 
on risk factors for autism.85 Comparing two depression-matched groups with and without 
antidepressant use may be methodologically more solid than adjusting analyses statistically. In 
addition, several adverse outcomes had small effect sizes on top of low prevalence and of no proof of 
a causal relationship between antidepressants and adverse health outcomes.  
Hence, given that a depressive episode itself can impair adolescents and both maternal and fetal 
health, individualized and shared clinical decisions about the benefit-risk ratio of antidepressants 
during adolescence and pregnancy should be implemented, but adolescence and pregnancy should 
not be considered absolute contraindications to the use of antidepressants.  
Limitations 
Several limitations should be mentioned. First, we did not grade the evidence from meta-
analyses of RCTs, covering a portion of available studies. However, evidence from RCTs is limited 
by the selection of healthier patients and frequent short-term follow-up, among other factors.16 Many 
severe adverse outcomes cannot be addressed in RCTs, and for low frequency and long-term health 
risks, observational research is the most feasible method.17 Nevertheless, observational research is 
not free from bias, either.18,86 Results from observational studies yield associations, which do not 
imply causality. Further, results in main analyses are affected by various confounders due to lack of 
randomization, potential channeling bias, and cofounding by indication.17,18,80 Specifically, the nature 
of the control groups was only insufficiently characterized, and there is evidence that when matching 
(and not adjusting) for the underlying psychiatric disorder, risk differences become smaller or non-
significant.43,44,51 Thus, the association with suicidality may be driven by antidepressants’ limited 
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efficacy in those suicidal children and adolescents according to results from RCTs,19 rather than 
being a direct effect of antidepressants on increasing suicidality. Notably, the association between 
ASD and SSRIs during pregnancy 52 included studies that were not adjusted for confounders (in 
contrast with weak evidence of any association between any antidepressants during pregnancy and 
ASD when adjusting for confounders 50 – eTable 4). Moreover, no inference can be made about 
newer antidepressants (e.g., vortioxetine), which have not been assessed in any of the included meta-
analyses. Furthermore, there was insufficient data on cardiometabolic outcomes; an emerging 
concern of the increased prescribing rates of antidepressants, and crucial area for future research.87 
Finally, our grading system can only provide warnings of the potential presence of systematic biases 
but cannot provide evidence of their nature and extent16,32,33 alongside umbrella reviews cannot 
supply any comparative ranking, as in network meta-analyses. 
Conclusions 
Our findings are important in the context of increased antidepressant use globally.1,2 An association 
between antidepressants and few adverse health outcomes with convincing evidence was observed, 
yet prevalence of those outcomes was on average low (range 0.1%-9.7%), and after accounting for 
confounding by indication, no association was supported by convincing evidence. Further research in 
both RCT and real-world samples matched for underlying disease is needed to confirm a possible 
causal association between antidepressants and adverse outcomes, considering dose-effect response, 
mechanistic processes, accounting for patient-specific characteristics, such as age, clinical diagnoses, 
and severity of clinical condition. No absolute contraindication against the use of antidepressants is 
currently supported by convincing evidence. 
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Table 1 Criteria for evaluation of the credibility of the evidence of observational studies 
Classification Criteria 
Convincing evidence (Class I) 1. More than 1000 cases 
2. Significant summary associations (p<1x10-6) 
per random-effects calculations 
3. No evidence of small-study effects 
4. No evidence of excess of significance bias 
5. Prediction intervals not including the null value 
6. Largest study nominally significant (p<0.05) 
7. No large heterogeneity (i.e., I2< 50%) 
Highly Suggestive evidence (Class II) 1. More than 1000 cases 
2. Significant summary associations (p<1x10-6) 
per random-effects calculation 
3. Largest study nominally significant (p<0.05) 
Suggestive Evidence (Class III) 1. More than 1000 cases 
2. Significant summary associations (p<1x10-3) 
per random-effects calculations 
Weak evidence (Class IV) 1. All other associations with p≤0.05 






Table 2 Convincing evidence (Class I) and highly suggestive evidence (Class II) for the association of antidepressants and risk of adverse health 
outcomes in meta-analyses of observational studies  
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Any AD users/  
No AD users 
0. 8% 7 RR, 1.48  
(1.29, 1.71) 
Increased 
risk for ADs 
22 877/ 
2 400 720  
6.8x10-8 24 
(0.244) 







SSRIs /  
Non-SSRIs users 





58 178 /  






No/NP Yes I Moderate 
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SSRIs /  
Non-SSRIs users 














SSRIs /  
Non-SSRIs users  






1 546 913 
1.3x10-44 88 
(<0.000) 
1.23-2.27 No/NP Yes  II Moderate 
Attention-deficit 
hyperactivity 
disorder in children  
(Man, 2018)48 
Prenatal exposure 
to ADs/ No AD 
users 
2. 4% 7 RR, 1.39 
(1.21,1.61) 
Increased 
risk for ADs 
 57 552/  
2 886 904 
5.1x10-6 79 
(<0.000) 




TCAs/ non-users or 
no users of any 
other AD 









0.56-2.52 No/NP Yes  II Moderate 
Severe bleeding at 
any site  
SSRIs+ SNRIs/ 
non-users or no 





1 443 029  
2.2x10-10 90 
(<0.000) 
0.77-2.59 No/No Yes II Low 
33 
 









(%) based on 



























(Jiang, 2016) 58 
Any AD users/ No 
AD users 
6. 8% 17 RR, 1.32 
(1.17, 1.48) 
Increased 





0.84-2.07 No/NP Yes II Low 
Upper GI bleeding 
(Jiang, 2015) 64 
 SSRIs+others non-
ADs/ No SSRIs use 
only+others non-
ADs 










0.83-2.91 No/No Yes  II Moderate 
Preterm birth 
(Huang, 2014) 66 
Any AD users/  
No AD users 
0. 8% 28 RR, 1.68 
(1.52, 1.86) 
Increased 






1.23-2.30 Yes/NP Yes II Moderate 
Osteoporotic 
fractures 
(Wu, 2013) 70 
TCAs users/ 
 Non-TCAs users 










1.04-2.01 Yes/No  Yes  II Moderate 
Apgar score at 5 
minutes 
Any AD users/  
No AD users 
2. 1% 15 SMD, -0.33 Increased 







No/No Yes  II Moderate 
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TCAs and/or SSRIs 
users/  
No AD users 











1.00-3.19 Yes/Yes Yes  II Critically low 
Suicide attempt and 
completion in adults  
(Barbui, 2009)80 
SSRIs / 
 Non- SSRIs users 










0.33-1.05 No/NP Yes  II High 
AD–antidepressants, APGAR – acronym of Appearance (skin color), Pulse (heart rate), Grimace (reflex irritability), Activity (muscle tone), and Respiration, CE – class of 
evidence, CI – confidence interval, ES – effect size, ESB –excess significance bias,  GI–gastrointestinal, I2 –heterogeneity, LS – largest study with significant effect, n – 
number of included studies per association, N – number of cases,  NA– not applicable, NP – not pertinent because the number of observed studies is less than the expected, 
OR – odds ratio, PI – prediction interval, RR – relative risk, SNRIs – serotonin–norepinephrine reuptake inhibitors, SSRIs – selective serotonin reuptake inhibitors, SMD–





Table 3 Sensitivity analysis for the associations between antidepressants use and risk of adverse health outcomes of class I-II associations 
limited to only cohort studies, prospective cohort, studies with adjustments for multiple covariates, studies adjusted for confounding by 
indication, high-quality studies, classes of antidepressants (SSRIs studies, TCAs studies, other or mixed antidepressants studies), and study 
location (Europe, North America, other regions)  
     Criteria used for classification of level of evidence 
















I2 (p) PI (95% 
CI) 
SSE/ESB LS CE CES / 
AMSTAR 
2 
Cohort studies (both retrospective and 
prospective) 
            
Autism spectrum disorders 
(pregnancy maternal exposure;  




0. 9% 3 OR, 1.65  
(1.37, 2.00) 
50 494 / 
5 790 186 
2.2x10-7 0 (0.692) 0.48-5.68 No/No Yes  I II/ 
Moderate 
Osteoporotic fractures  
(Khanassov, 2018)42  
  
SSRIs /  
Non-SSRIs users 












Any AD users/ Non-
AD users 
0. 8% 24 RR, 1.67 
(1.51, 1.86) 
24 378/ 
3 063 012 
6.5x10-22 49 
(0.004) 
1.21-2.33 Yes/No Yes II II / 
Moderate 
Apgar score at 5 minutes 
(Ross, 2013)71 
Any AD users/ Non-
AD users 







-1.02, 0.36 No/No Yes  II II / 
Moderate 
Suicide attempt and completion in children 
and adolescents 
(Barbui, 2009)80 
SSRIs / Non-SSRIs 
users 




1.8x10-7 0 (0.463) 0.36-9.85 No/NP Yes  I II / 
 High 
Suicide attempt and completion in adults  
(Barbui, 2009)80 
SSRIs / Non-SSRIs 
users 
4.5% 5 OR, 0.53 
(0.43, 0.66) 




0.27-1.04 No/NP Yes  II II /  
High 
Prospective cohort studies             
Autism spectrum disorders 
(pregnancy maternal exposure;  




0. 9% 3 OR, 1.65  
(1.37, 2.00) 
50 494 / 
5 790 186 




Any AD users/ Non-
AD users 







1.17-3.00 No/NP Yes II I / 
Moderate 
Studies with adjustments for multiple 
covariates  
            
Autism spectrum disorders (Pre-pregnancy 
maternal exposure; Morales, 2018)51 
Any AD users/  
No AD users 
0. 8% 7 RR, 1.48  
(1.29, 1.71) 
22 877/ 
2 400 720  
6.8x10-8 24 
(0.244) 




Suicide attempt and completion in children 
and adolescents 
(Barbui, 2009)80 
SSRIs /  
Non-SSRIs users 
9. 4%  5 OR, 1.92 
(1.51, 2.44) 
6 531/  
61 522 
 
1.0x10-7 0 (0.469) 1.30–2.84 No/NP Yes I I /  
High 
Osteoporotic fractures  
(Khanassov, 2018)42 
SSRIs /  
Non-SSRIs users  
6.5% 22 RR, 1.67 
(1.53, 1.82) 
96 353/ 
929 936  
6.6x10-33 88 
(<0.000) 
1.17-2.38 No/NP Yes II II/ 
Moderate 
Attention-deficit hyperactivity disorder in 
children  
(Man, 2018)48 
Prenatal exposure to 
ADs/ No AD users 
2. 4% 7 RR, 1.39 
(1.21,1.61) 
 57 552/  
2 886 904 
5.1x10-6 79 
(<0.000) 
0.90–2.15 No/NP Yes  II II/ 
Moderate 
Upper GI bleeding 
(Jiang, 2015) 64 
 SSRIs+others non-
ADs/ No SSRIs use 
only+others non-
ADs 











 Non-TCAs users 
NA 11 RR, 1.43 
(1.29, 1.58) 
178 237 / 
740 768  
1.9 x10-12 77 
(<0.000) 




TCAs and/or SSRIs 
users/  
No AD users 







0.96-3.24 Yes/No  Yes  II II / 
Critically 
low 
Studies adjusted for confounding by 
indication 
            
Autism spectrum disorders (Pre-pregnancy 
maternal exposure; Morales, 2018)51 
Any AD users/  
No AD users 
1.1% 3 RR, 1.69  
(1.39, 2.05) 
3 016/ 
 667 431 
 
1.0 x10-7 0 
(0.735) 





Suicide attempt and completion in children 
and adolescents 
(Barbui, 2009)80 
SSRIs /  
Non-SSRIs users 
9.7%  4 OR, 2.04 
(1.23, 3,41) 




0.47-8.81 Yes/NP No I IV /  
High 
Osteoporotic fractures  
(Khanassov, 2018)42 
SSRIs /  
Non-SSRIs users  












 Non-TCAs users 






0.98-2.22 No/No  Yes  II  II / 
Moderate 
High-quality primary studies              
Autism spectrum disorders  
(Pre-pregnancy maternal exposure;  
Morales, 2018)51 
Any AD users/  
No AD users 
0. 8% 7 RR, 1.48  
(1.29, 1.71) 
22 877/ 
2 400 720  
6.8x10-8 24 
(0.244) 
1.09–2.02 No/NP Yes I I/ 
Moderate 
Autism spectrum disorders  
(pregnancy maternal exposure; unadjusted 
estimates only; Andalib, 2017)52 
SSRIs /  
Non-SSRIs users 
0. 9% 7 OR, 1.84 
(1.60, 2.11) 
58 178 /  
5 868 692 
 
1.2x10-17 0 (0.729) 1.53–2.20 
 
No/NP Yes I I/ 
Moderate 
Suicide attempt and completion in children 
and adolescents 
(Barbui, 2009)80 
SSRIs /  
Non-SSRIs users 
3.6%  4 OR, 1.88 
(1.47, 2.40) 
5 961/  
30 343  
3.5x10-7 0 
(0.496) 
1.10-3.21 No/NP Yes  I I/ 
High 
Osteoporotic fractures  
(Khanassov, 2018)42  
  
SSRIs /  
Non-SSRIs users 
6. 6% 20 RR, 1.70 
(1.57, 1.85) 
117 567/ 
 1 053 697 
9.6x10-37 88 
(<0.000) 
1.23-2.35 No/NP Yes  II II/ 
Moderate  
Attention-deficit hyperactivity disorder in 
children  
Prenatal exposure to 
ADs/ No AD users 
2. 4% 7 RR, 1.39 
(1.21,1.61) 
 57 552/  
2 886 904 
5.1x10-6 79 
(<0.000) 





Postpartum hemorrhage  
(Jiang, 2016)58 
Any AD users/ No 
AD users 
6. 8% 16 RR, 1.32 
(1.17, 1.48) 
49 142/  
651 439  
3.7x10-6 86 
(<0.000) 




Any AD users/  
No AD users 
0. 3% 19 RR, 1.86 
(1.59, 2.19) 
5 116/ 
1 658 666 
5.3x10-14 52 
(0.004) 





 Non-TCAs users 
NA 9 RR, 1.46 
(1.30, 1.65) 
36 865/ 
247 078  
6.0x10-10 82 
(<0.000) 




TCAs and/or SSRIs 
users/  
No AD users 
NA 6 OR, 1.59 
(1.31, 1.92) 
41 227/ 
159 831  
2.5x10-7 91 
(<0.000) 
0.82-3.07 Yes/No  Yes  II II/ 
Critically 
low 
Suicide attempt and completion in adults  
(Barbui, 2009)80 
SSRIs / 
 Non- SSRIs users 
4.5% 7 OR, 0.59 
(0.48, 0.72) 





0.33-1.05 No/NP Yes  II II/  
High 
SSRIs studies              
Autism spectrum disorders  
(pregnancy maternal exposure; unadjusted 
estimates only; Andalib, 2017) 52 
SSRIs /  
Non-SSRIs users 
0. 9% 7 OR, 1.84 
(1.60, 2.11) 
58 178 /  
5 868 692 
 
1.2x10-17 0 (0.729) 1.53–2.20 
 
No/NP Yes I I/ 
Moderate  
Suicide attempt and completion in children 
and adolescents 
(Barbui, 2009)80 
SSRIs /  
Non-SSRIs users 
9. 4% 5 OR, 1.92 
(1.51, 2.44) 
6 531/  
61 522 
 
1.0x10-7 0 (0.469) 1.30–2.84 No/NP Yes  I I / 
High 
Apgar score at 5 minutes 
(Ross, 2013)71 
SSRIs /  
Non-SSRIs users 











Osteoporotic fractures  
(Khanassov, 2018)42 
SSRIs /  
Non-SSRIs users  
6. 5% 24 RR, 1.67 
(1.56, 1.80) 
136 449/ 
1 546 913 
1.3x10-44 88 
(<0.000) 




SSRIs /  
Non-SSRIs users 
9. 7% 20 RR, 1.73 
(1.53, 1.96) 
21 163/ 




1.22-2.46 Yes/NP Yes II II / 
Moderate 
Suicide attempt and completion in adults  
(Barbui, 2009)80 
SSRIs / 
 Non- SSRIs users 
3. 5% 7 OR, 0.59 
(0.48, 0.72) 





0.33-1.05 No/NP Yes  II II / 
 High 
TCAs studies              
Cataract development 
(Fu, 2018)49 
TCAs/ non-users or 
no users of any other 
AD 




















1.04-2.01 Yes/No  Yes  II II / 
Moderate 
Other or mixed AD studies              
Autism spectrum disorders  




0. 8% 7 RR, 1.48  
(1.29, 1.71) 
22 877/ 
2 400 720  
6.8x10-8 24 
(0.244) 




















6. 8% 44 OR, 1.41 
(1.27,1.57) 
190 016/ 




0.77-2.59 No/No Yes II II /  
Low 










0.84-2.07 No/NP Yes II II / 
 Low 
Upper GI bleeding 
(Jiang, 2015) 64 







0.83-2.91 No/No Yes  II II / 
Moderate 
European studies              
Autism spectrum disorders  
(pregnancy maternal exposure; unadjusted 
estimates only; Andalib, 2017)52  
SSRIs /  
Non-SSRIs users 
0. 1% 4 OR, 1.80 
(1.54, 2.10) 
6 394/  
5 741 029 
 
1.1x10-13 0 (0.396) 1.28–2.53 
 
No/No Yes I I/ 
Moderate  
Osteoporotic fractures  
(Khanassov, 2018)42 
SSRIs /  
Non-SSRIs users  
6. 5% 12 RR, 1.76 
(1.68, 1.87) 
92 760/ 
1 228 807 
2.3x10-86 67 
(<0.000) 
1.50-2.07 No/No Yes II II/ 
Moderate  
Upper GI bleeding 
(Jiang, 2015) 64 
SSRIs+others non-
ADs/ No SSRIs use 
only+others non-
ADs 










Any AD users/  
No AD users 
0. 9% 7 RR, 1.61 
(1.36, 1.92) 
17 518/ 









 Non-TCAs users 










AD–antidepressants, CE- class of evidence (main analysis), CES – class of evidence after sensitivity analysis, CI – confidence interval, ES – effect size, ESB –excess 
significance bias,  GI–gastrointestinal, I2 –heterogeneity, LS – largest study with significant effect, n – number of included studies per association, N – number of cases,  NA– 
not applicable, NP – not pertinent because the number of observed studies is less than the expected, OR – odds ratio, PI – prediction interval, RR – relative risk, SNRIs – 




TCAs and/or SSRIs 
users/  
No AD users 






0.88.3.42 Yes/No Yes II II / 
Critically 
low 
North America studies             
Osteoporotic fractures  
(Khanassov, 2018)42 
SSRIs /  
Non-SSRIs users  










Any AD users/  
No AD users 
0.6% 17 RR, 1.70 
(1.44, 1.99) 










 Non-TCAs users 
NA 6 RR, 1.54 
(1.32, 1.81) 
13 761 / 
84 583 
7.3 x10-8 76 
(0.001) 




TCAs and/or SSRIs 
users/  
No AD users 






1.01-3.27 No/NP Yes  II II/ 
Critically 
low 
Other regions  
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(("serotonin uptake inhibitors"[Pharmacological Action] OR "serotonin uptake inhibitors"[MeSH Terms] OR 
("serotonin"[All Fields] AND "uptake"[All Fields] AND "inhibitors"[All Fields]) OR "serotonin uptake 
inhibitors"[All Fields] OR ("selective"[All Fields] AND "serotonin"[All Fields] AND "reuptake"[All Fields] AND 
"inhibitors"[All Fields]) OR "selective serotonin reuptake inhibitors"[All Fields]) OR ("serotonin uptake 
inhibitors"[Pharmacological Action] OR "serotonin uptake inhibitors"[MeSH Terms] OR ("serotonin"[All 
Fields] AND "uptake"[All Fields] AND "inhibitors"[All Fields]) OR "serotonin uptake inhibitors"[All Fields] OR 
"ssris"[All Fields]) OR ("antidepressive agents"[Pharmacological Action] OR "antidepressive agents"[MeSH 
Terms] OR ("antidepressive"[All Fields] AND "agents"[All Fields]) OR "antidepressive agents"[All Fields] OR 
"antidepressants"[All Fields]) OR (antidepranalgesia[All Fields] OR antidepredatory[All Fields] OR 
antideprein[All Fields] OR antidepres[All Fields] OR antidepres'iva[All Fields] OR antidepres'ivn'i[All Fields] 
OR antidepres'ivn'ich[All Fields] OR antidepres'ivy[All Fields] OR antidepresan[All Fields] OR 
antidepresant[All Fields] OR antidepresanti[All Fields] OR antidepresants[All Fields] OR antidepresantu[All 
Fields] OR antidepresessant[All Fields] OR antidepreseurs[All Fields] OR antidepresiv[All Fields] OR 
antidepresiva[All Fields] OR antidepresivach[All Fields] OR antidepresivami[All Fields] OR antidepresivas[All 
Fields] OR antidepresive[All Fields] OR antidepresivem[All Fields] OR antidepresives[All Fields] OR 
antidepresivi[All Fields] OR antidepresivima[All Fields] OR antidepresivinm[All Fields] OR 
antidepresivnaih[All Fields] OR antidepresivni[All Fields] OR antidepresivnich[All Fields] OR 
antidepresivniho[All Fields] OR antidepresivnim[All Fields] OR antidepresivnimu[All Fields] OR 
antidepresivnych[All Fields] OR antidepresivo[All Fields] OR antidepresivos[All Fields] OR 
antidepresivum[All Fields] OR antidepresivy[All Fields] OR antidepresor[All Fields] OR antidepress[All 
Fields] OR antidepressand[All Fields] OR antidepressani[All Fields] OR antidepressanov[All Fields] OR 
antidepressans[All Fields] OR antidepressant[All Fields] OR antidepressant'[All Fields] OR 
antidepressant's[All Fields] OR antidepressanta[All Fields] OR antidepressantam[All Fields] OR 
antidepressantami[All Fields] OR antidepressanteffects[All Fields] OR antidepressantinduced[All Fields] OR 
antidepressantlike[All Fields] OR antidepressantlithium[All Fields] OR antidepressantnogo[All Fields] OR 
antidepressantom[All Fields] OR antidepressantov[All Fields] OR antidepressants[All Fields] OR 
antidepressants'[All Fields] OR antidepressantswere[All Fields] OR antidepressantu[All Fields] OR 
antidepressantv[All Fields] OR antidepressanty[All Fields] OR antidepressed[All Fields] OR 
antidepressent[All Fields] OR antidepressents[All Fields] OR antidepresseur[All Fields] OR 
antidepresseurs[All Fields] OR antidepresseurs'[All Fields] OR antidepresseus[All Fields] OR 
antidepresseuses[All Fields] OR antidepressia[All Fields] OR antidepressief[All Fields] OR 
antidepressieve[All Fields] OR antidepressiewe[All Fields] OR antidepressif[All Fields] OR antidepressifs[All 
Fields] OR antidepressiivien[All Fields] OR antidepressiiviset[All Fields] OR antidepressin[All Fields] OR 
antidepressing[All Fields] OR antidepression[All Fields] OR antidepressions[All Fields] OR 
antidepressionsbehandling[All Fields] OR antidepressiu[All Fields] OR antidepressiv[All Fields] OR 
antidepressiva[All Fields] OR antidepressivabehandling[All Fields] OR antidepressivarichtlijnen[All Fields] 
OR antidepressivas[All Fields] OR antidepressivastudien[All Fields] OR antidepressivasubstanzen[All Fields] 
OR antidepressivatherapie[All Fields] OR antidepressive[All Fields] OR antidepressively[All Fields] OR 
antidepressivem[All Fields] OR antidepressiven[All Fields] OR antidepressivene[All Fields] OR 
antidepressiver[All Fields] OR antidepressives[All Fields] OR antidepressivi[All Fields] OR 
antidepressivnikh[All Fields] OR antidepressivnoe[All Fields] OR antidepressivnogo[All Fields] OR 
antidepressivnoi[All Fields] OR antidepressivnom[All Fields] OR antidepressivnye[All Fields] OR 
antidepressivnyi[All Fields] OR antidepressivnykh[All Fields] OR antidepressivnymi[All Fields] OR 
antidepressivo[All Fields] OR antidepressivos[All Fields] OR antidepressivt[All Fields] OR 
antidepressivum[All Fields] OR antidepressivum'[All Fields] OR antidepressivums[All Fields] OR 
         
         
         




































antidepressziv[All Fields] OR antidepresszivum[All Fields] OR antidepresszivumhasznalat[All Fields] OR 
antidepresszivumok[All Fields] OR antidepresszivumot[All Fields] OR antideprimenti[All Fields] OR 
antideprin[All Fields] OR antideprssants[All Fields] OR antideprssiva[All Fields] OR antideprssives[All 
Fields]) OR ("citalopram"[MeSH Terms] OR "citalopram"[All Fields]) OR ("citalopram"[MeSH Terms] OR 
"citalopram"[All Fields] OR "escitalopram"[All Fields]) OR ("fluoxetine"[MeSH Terms] OR "fluoxetine"[All 
Fields]) OR ("fluvoxamine"[MeSH Terms] OR "fluvoxamine"[All Fields]) OR ("paroxetine"[MeSH Terms] OR 
"paroxetine"[All Fields]) OR ("sertraline"[MeSH Terms] OR "sertraline"[All Fields]) OR ("monoamine 
oxidase inhibitors"[Pharmacological Action] OR "monoamine oxidase inhibitors"[MeSH Terms] OR 
("monoamine"[All Fields] AND "oxidase"[All Fields] AND "inhibitors"[All Fields]) OR "monoamine oxidase 
inhibitors"[All Fields] OR "maoi"[All Fields]) OR ("antidepressive agents, tricyclic"[Pharmacological Action] 
OR "antidepressive agents, tricyclic"[MeSH Terms] OR ("antidepressive"[All Fields] AND "agents"[All 
Fields] AND "tricyclic"[All Fields]) OR "tricyclic antidepressive agents"[All Fields] OR ("tricyclic"[All Fields] 
AND "antidepressant"[All Fields]) OR "tricyclic antidepressant"[All Fields]) OR ("Theor Chem Acc"[Journal] 
OR "tca"[All Fields]) OR (("serotonin"[MeSH Terms] OR "serotonin"[All Fields]) AND 
("norepinephrine"[MeSH Terms] OR "norepinephrine"[All Fields] OR "noradrenaline"[All Fields]) AND 
reuptake[All Fields] AND inhibitor[All Fields]) OR ("serotonin and noradrenaline reuptake 
inhibitors"[Pharmacological Action] OR "serotonin and noradrenaline reuptake inhibitors"[MeSH Terms] 
OR ("serotonin"[All Fields] AND "noradrenaline"[All Fields] AND "reuptake"[All Fields] AND 
"inhibitors"[All Fields]) OR "serotonin and noradrenaline reuptake inhibitors"[All Fields] OR "snri"[All 
Fields]) OR (("serotonin antagonists"[Pharmacological Action] OR "serotonin antagonists"[MeSH Terms] 
OR ("serotonin"[All Fields] AND "antagonists"[All Fields]) OR "serotonin antagonists"[All Fields] OR 
("serotonin"[All Fields] AND "antagonist"[All Fields]) OR "serotonin antagonist"[All Fields]) AND 
reuptake[All Fields] AND inhibitor[All Fields]) OR SARI[All Fields] OR (("norepinephrine"[MeSH Terms] OR 
"norepinephrine"[All Fields]) AND ("dopamine uptake inhibitors"[Pharmacological Action] OR "dopamine 
uptake inhibitors"[MeSH Terms] OR ("dopamine"[All Fields] AND "uptake"[All Fields] AND "inhibitors"[All 
Fields]) OR "dopamine uptake inhibitors"[All Fields] OR ("dopamine"[All Fields] AND "reuptake"[All Fields] 
AND "inhibitor"[All Fields]) OR "dopamine reuptake inhibitor"[All Fields])) OR NDRI[All Fields] OR 
(("norepinephrine"[MeSH Terms] OR "norepinephrine"[All Fields]) AND reuptake[All Fields] AND 
inhibitor[All Fields]) OR NRI[All Fields] OR (noradrenergic[All Fields] AND specific[All Fields] AND 
serotonergic[All Fields] AND ("antidepressive agents"[Pharmacological Action] OR "antidepressive 
agents"[MeSH Terms] OR ("antidepressive"[All Fields] AND "agents"[All Fields]) OR "antidepressive 
agents"[All Fields] OR "antidepressant"[All Fields])) OR NaSSA[All Fields]) AND (("suicide"[MeSH Terms] 
OR "suicide"[All Fields]) OR ("suicidal ideation"[MeSH Terms] OR ("suicidal"[All Fields] AND "ideation"[All 
Fields]) OR "suicidal ideation"[All Fields]) OR (("suicide"[MeSH Terms] OR "suicide"[All Fields]) AND 
("risk"[MeSH Terms] OR "risk"[All Fields])) OR (serious[All Fields] AND adverse[All Fields] AND events[All 
Fields]) OR ("adverse effects"[Subheading] OR ("adverse"[All Fields] AND "effects"[All Fields]) OR 
"adverse effects"[All Fields] OR ("side"[All Fields] AND "effects"[All Fields]) OR "side effects"[All Fields]) 
OR harm[All Fields] OR ("fractures, bone"[MeSH Terms] OR ("fractures"[All Fields] AND "bone"[All Fields]) 
OR "bone fractures"[All Fields] OR ("bone"[All Fields] AND "fractures"[All Fields])) OR ("psychomotor 
agitation"[MeSH Terms] OR ("psychomotor"[All Fields] AND "agitation"[All Fields]) OR "psychomotor 
agitation"[All Fields] OR "akathisia"[All Fields]) OR ("photosensitivity disorders"[MeSH Terms] OR 
("photosensitivity"[All Fields] AND "disorders"[All Fields]) OR "photosensitivity disorders"[All Fields] OR 
"photosensitivity"[All Fields]) OR (("sexual behavior"[MeSH Terms] OR ("sexual"[All Fields] AND 
"behavior"[All Fields]) OR "sexual behavior"[All Fields] OR "sexual"[All Fields]) AND 
("physiopathology"[Subheading] OR "physiopathology"[All Fields] OR "dysfunction"[All Fields])) OR 
("coronary disease"[MeSH Terms] OR ("coronary"[All Fields] AND "disease"[All Fields]) OR "coronary 


































"coronary heart disease"[All Fields]) OR ("hemorrhage"[MeSH Terms] OR "hemorrhage"[All Fields] OR 
"bleeding"[All Fields]) OR (("fractures, bone"[MeSH Terms] OR ("fractures"[All Fields] AND "bone"[All 
Fields]) OR "bone fractures"[All Fields] OR "fracture"[All Fields]) AND ("risk"[MeSH Terms] OR "risk"[All 
Fields])) OR (discontinuation[All Fields] AND ("syndrome"[MeSH Terms] OR "syndrome"[All Fields])) OR 
("serotonin syndrome"[MeSH Terms] OR ("serotonin"[All Fields] AND "syndrome"[All Fields]) OR 
"serotonin syndrome"[All Fields]) OR ("neonatal abstinence syndrome"[MeSH Terms] OR ("neonatal"[All 
Fields] AND "abstinence"[All Fields] AND "syndrome"[All Fields]) OR "neonatal abstinence syndrome"[All 
Fields]) OR ("autistic disorder"[MeSH Terms] OR ("autistic"[All Fields] AND "disorder"[All Fields]) OR 
"autistic disorder"[All Fields] OR "autism"[All Fields])) AND (("meta-analysis"[Publication Type] OR "meta-
analysis as topic"[MeSH Terms] OR "meta-analysis"[All Fields]) OR ("meta-analysis as topic"[MeSH Terms] 
OR ("meta-analysis"[All Fields] AND "topic"[All Fields]) OR "meta-analysis as topic"[All Fields] OR 




eTable 1 Articles excluded after full-text revision, with reasons 
 
Author, year (Reference) Reason for exclusion 
        Ng, 2019 1 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
        Patel, 2019 2  Not reporting an association of antidepressants and risk of adverse health outcomes 
       Rexwinkel, 2019 3 Nether a meta-analysis or systematic review with quantitative synthesis  
       Perlman, 2019 4  Nether a meta-analysis or systematic review with quantitative synthesis 
       Amare, 2019 5 Not reporting an association of antidepressants and risk of adverse health outcomes  
       Aguiar, 2019 6 Nether a meta-analysis or systematic review with quantitative synthesis 
       Zhou, 20187 Not included only case-control and cohort studies 
Wu, 2018 8 Not reporting an association of antidepressants and risk of adverse health outcomes 
Wang, 2018 9  Nether a meta-analysis or systematic review with quantitative synthesis  
Visco, 201810 Not included only case-control and cohort studies 
Uguz,  2018 11 Nether a meta-analysis or systematic review with quantitative synthesis  
Tan, 201812 Not a meta-analysis or systematic review of observational studies 
Telang, 2018 13 Not a meta-analysis or systematic review of observational studies 
Sepehripour, 201814 Nether a meta-analysis or systematic review with quantitative synthesis  
Prady, 2018 15 Nether a meta-analysis or systematic review with quantitative synthesis  
Cappetta, 201816 Not a meta-analysis or systematic review of observational studies 
Steinert, 201817 Nether a meta-analysis or systematic review with quantitative synthesis 
Melo, 201818 Not included only case-control and cohort studies 
Moncrieff, 201819 Nether a meta-analysis or systematic review with quantitative synthesis  
Douros, 2018 20 Nether a meta-analysis or systematic review with quantitative synthesis 
Chen, 201821 Not a meta-analysis or systematic review of observational studies 
Comoretto, 2018 22 Not reporting an association of antidepressants and risk of adverse health outcomes  
Varney, 2017 23 Nether a meta-analysis or systematic review with quantitative synthesis 
Uguz, 2017 24 Nether a meta-analysis or systematic review with quantitative synthesis 
Salvi, 201725 Not included only case-control and cohort studies 
Stubbs, 2017 26 Nether a meta-analysis or systematic review with quantitative synthesis 
Riediger, 2017 27 Not a meta-analysis or systematic review of observational studies 
Querido, 2017 28 Nether a meta-analysis or systematic review with quantitative synthesis 
Mezzacappa, 201729 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Maund, 2017 30 Not a meta-analysis or systematic review of observational studies 
Moraros, 201731 Not included only case-control and cohort studies  
Locher, 2017 32 Not a meta-analysis or systematic review of observational studies 
Laux, 2017 33 Nether a meta-analysis or systematic review with quantitative synthesis 
Kaplan, 2017 34 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Heller, 2017 35 Nether a meta-analysis or systematic review with quantitative synthesis 
Hill, 201736 Not included only case-control and cohort studies 
Deidda, 2017 37 Nether a meta-analysis or systematic review with quantitative synthesis 
Brunnauer,  2017 38 Nether a meta-analysis or systematic review with quantitative synthesis 
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Brown, 2017 39 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Beyer, 2017 40 Not a meta-analysis or systematic review of observational studies 
Andrade, 2017 41 Nether a meta-analysis or systematic review with quantitative synthesis 
Allain, 2017 42 Nether a meta-analysis or systematic review with quantitative synthesis 
Vlachos, 2016 43 Nether a meta-analysis or systematic review with quantitative synthesis 
Werneke, 2016 44 Not reporting an association of antidepressants and risk of adverse health outcomes 
Warden, 2016 45 Nether a meta-analysis or systematic review with quantitative synthesis 
Torjesen, 2016 46 Commentary 
Stone, 2016 47 Commentary 
Smit, 2016 48 Nether a meta-analysis or systematic review with quantitative synthesis 
Simonsen, 2016 49 Nether a meta-analysis or systematic review with quantitative synthesis 
Sharma, 2016 50 Nether a meta-analysis or systematic review with quantitative synthesis  
Selmer, 2016 51 Insufficient or inadequate data for quantitative synthesis provided  
Rudisill, 2016 52  Insufficient or inadequate data for quantitative synthesis provided 
Pozzi, 2016 53 Nether a meta-analysis or systematic review with quantitative synthesis 
Potočnjak, 2016 54 Nether a meta-analysis or systematic review with quantitative synthesis 
Muzik, 2016 55  Nether a meta-analysis or systematic review with quantitative synthesis 
Lassen, 2016 56  Insufficient or inadequate data for quantitative synthesis provided 
Kaplan, 2016 57 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Kobayashi, 2016 58 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Jordan, 2016 59 Nether a meta-analysis or systematic review with quantitative synthesis 
Jarde, 2016 60  Not reporting an association of antidepressants and risk of adverse health outcomes 
Howland, 2016 61 Nether a meta-analysis or systematic review with quantitative synthesis 
Galling, 2016 62 Not reporting an association of antidepressants and risk of adverse health outcomes 
Donneyong, 2016 63 Nether a meta-analysis or systematic review with quantitative synthesis 
Cameron, 2016 64 Nether a meta-analysis or systematic review with quantitative synthesis 
Braun, 2016 65 Not a meta-analysis or systematic review of observational studies 
Bielefeldt, 2016 66 Not a meta-analysis or systematic review of observational studies 
Barth, 2016 67 Not a meta-analysis or systematic review of observational studies 
Akioyamen, 2016 68 Nether a meta-analysis or systematic review with quantitative synthesis 
Alvares, 201669 Not included only case-control and cohort studies 
Wang, 2015 70 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Uchida, 2015 71 Nether a meta-analysis or systematic review with quantitative synthesis 
Thase, 2015 72 Nether a meta-analysis or systematic review with quantitative synthesis 
Teo, 2015 73 Nether a meta-analysis or systematic review with quantitative synthesis 
Tampi, 2015 74 Nether a meta-analysis or systematic review with quantitative synthesis 
Stubbs, 2015 75 Commentary 
Santarsieri, 2015 76 Nether a meta-analysis or systematic review with quantitative synthesis 
Robinson, 2015 77 Commentary 
Renoux, 2015 78 Nether a meta-analysis or systematic review with quantitative synthesis 
Pinheiro, 2015 79 Insufficient or inadequate data for quantitative synthesis provided  
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Orsolini, 2015 80 Nether a meta-analysis or systematic review with quantitative synthesis 
Olfson, 2015 81 Nether a meta-analysis or systematic review with quantitative synthesis 
Nezafati, 2015 82 Nether a meta-analysis or systematic review with quantitative synthesis 
Mohler, 2015 83 Commentary 
Man, 2015 84 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
KoKoAung, 2015 85 Full-text could not retrieved 
Gøtzsche, 2015 86 Commentary 
Gentile, 2015 87 Nether a meta-analysis or systematic review with quantitative synthesis 
Gentile, 2015 88 Nether a meta-analysis or systematic review with quantitative synthesis 
Gebara, 2015 89 Nether a meta-analysis or systematic review with quantitative synthesis 
Ennis, 2015 90 Not reporting an association of antidepressants and risk of adverse health outcomes 
Davis, 2015 91 Not reporting an association of antidepressants and risk of adverse health outcomes 
Correll, 2015 92 Nether a meta-analysis or systematic review with quantitative synthesis 
Bruning, 2015 93 Nether a meta-analysis or systematic review with quantitative synthesis 
Stevenson, 2014 94 Nether a meta-analysis or systematic review with quantitative synthesis 
Ross, 2014 95 Commentary 
Rais, 2014 96 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Park, 201597 Not included only case-control and cohort studies 
Prieto-Alhambra, 2014 98 Nether a meta-analysis or systematic review with quantitative synthesis 
Previti, 2014 99 Nether a meta-analysis or systematic review with quantitative synthesis 
Pereira, 2014 100 Nether a meta-analysis or systematic review with quantitative synthesis 
Pedersen, 2014 101 Nether a meta-analysis or systematic review with quantitative synthesis 
Paumgartten, 2014 102 Nether a meta-analysis or systematic review with quantitative synthesis 
Okazaki, 2014 103 Nether a meta-analysis or systematic review with quantitative synthesis 
Oka, 2014 104 Insufficient or inadequate data for quantitative synthesis provided  
McDonagh, 2014 105 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Mahdanian, 2014 106 Nether a meta-analysis or systematic review with quantitative synthesis 
Mago, 2014 107 Nether a meta-analysis or systematic review with quantitative synthesis 
Lorenzo, 2014 108 Nether a meta-analysis or systematic review with quantitative synthesis 
Li, 2014 109 Nether a meta-analysis or systematic review with quantitative synthesis 
Isacsson, 2014 110 Nether a meta-analysis or systematic review with quantitative synthesis 
Grigoriadis, 2014 111 Nether a meta-analysis or systematic review with quantitative synthesis 
Gebara, 2014 112 Nether a meta-analysis or systematic review with quantitative synthesis 
Fanoe, 2014 113 Nether a meta-analysis or systematic review with quantitative synthesis 
El Marroun, 2014 114 Nether a meta-analysis or systematic review with quantitative synthesis 
Costoloni, 2014 115 Nether a meta-analysis or systematic review with quantitative synthesis 
Clayton, 2014 116 Nether a meta-analysis or systematic review with quantitative synthesis 
Beach, 2014 117 Insufficient or inadequate data for quantitative synthesis provided 
Anglin, 2014 118 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Andrade, 2014 119 Nether a meta-analysis or systematic review with quantitative synthesis 
Rotella, 2013 120 Not reporting an association of antidepressants and risk of adverse health outcomes 
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Rabenda, 2013 121 Insufficient or inadequate data for quantitative synthesis provided 
Painuly, 2013122 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Nassir, 2013 123 Nether a meta-analysis or systematic review with quantitative synthesis 
Myles, 2013 124 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Mintzes, 2013 125 Commentary 
Kennedy, 2013 126 Commentary 
Howland, 2013 127 Nether a meta-analysis or systematic review with quantitative synthesis 
Grigoriadis, 2013 128 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Grigoriadis, 2013 129 Nether a meta-analysis or systematic review with quantitative synthesis 
Gahr, 2013 130 Nether a meta-analysis or systematic review with quantitative synthesis 
De Jong, 2013 131 Nether a meta-analysis or systematic review with quantitative synthesis 
De Groot, 2013 132 Nether a meta-analysis or systematic review with quantitative synthesis 
Brunnauer, 2013 133 Nether a meta-analysis or systematic review with quantitative synthesis 
Bhattacharjee,  2013 134 Not included only case-control and cohort studies 
Barnard, 2013 135 Nether a meta-analysis or systematic review with quantitative synthesis 
Al-Zoairy, 2013 136 Nether a meta-analysis or systematic review with quantitative synthesis 
Wu, 2012 137 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
T Jong, 2012 138 Nether a meta-analysis or systematic review with quantitative synthesis 
Sansone, 2012 139 Nether a meta-analysis or systematic review with quantitative synthesis 
Pan, 2012 140 Nether a meta-analysis or systematic review with quantitative synthesis 
Oyebode, 2012 141 Nether a meta-analysis or systematic review with quantitative synthesis 
Nischal,  2012 142 Nether a meta-analysis or systematic review with quantitative synthesis 
Malm, 2012 143 Nether a meta-analysis or systematic review with quantitative synthesis 
Lopez-Yarto, 2012 144 Insufficient or inadequate data for quantitative synthesis provided  
Kucukaycan, 2012 145 Nether a meta-analysis or systematic review with quantitative synthesis 
KoKoAung, 2012 146 Full-text could not retrieved 
Hennings, 2012 147 Nether a meta-analysis or systematic review with quantitative synthesis 
Hackam, 2012 148 Insufficient or inadequate data for quantitative synthesis provided  
Grzeskowiak, 2012 149 Nether a meta-analysis or systematic review with quantitative synthesis 
Einarson, 2012 150  Nether a meta-analysis or systematic review with quantitative synthesis 
Eom, 2012151 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Colotto, 2012 152 Nether a meta-analysis or systematic review with quantitative synthesis 
Bromley, 2012 153 Nether a meta-analysis or systematic review with quantitative synthesis 
Adams, 2012 154 Not reporting an association of antidepressants and risk of adverse health outcomes 
Gentile,  2011155 Nether a meta-analysis or systematic review with quantitative synthesis 
Gentile,  2011 156 Nether a meta-analysis or systematic review with quantitative synthesis 
Fenger-Gron, 2011 157 Nether a meta-analysis or systematic review with quantitative synthesis 
Davanzo, 2011 158 Nether a meta-analysis or systematic review with quantitative synthesis 
Dassanayake, 2011 159 Not reporting an association of antidepressants and risk of adverse health outcomes 
Berkowitz, 2011 160 Nether a meta-analysis or systematic review with quantitative synthesis 
Barbui, 2011161 Nether a meta-analysis or systematic review with quantitative synthesis 
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Wurst, 2010 162 Insufficient or inadequate data for quantitative synthesis provided  
Wu, 2010 163 Not reporting an association of antidepressants and risk of adverse health outcomes 
Van Driel,  2010 164 Nether a meta-analysis or systematic review with quantitative synthesis 
Udechuku, 2010 165 Nether a meta-analysis or systematic review with quantitative synthesis 
Tuccori, 2010 166 Nether a meta-analysis or systematic review with quantitative synthesis 
Simoncelli, 2010 167 Nether a meta-analysis or systematic review with quantitative synthesis 
Scialli, 2010 168 Commentary 
Kemp, 2010 169 Not included only case-control and cohort studies 
Kölch, 2010 170 Nether a meta-analysis or systematic review with quantitative synthesis 
Kontakioti, 2010 171 Nether a meta-analysis or systematic review with quantitative synthesis 
Einarson, 2010 172 Commentary 
Einarson, 2010 173 Nether a meta-analysis or systematic review with quantitative synthesis 
Berard, 2010 174 Commentary 
Woolcott, 2009 175 Not included only case-control and cohort studies 
Fortinguerra, 2009 176 Nether a meta-analysis or systematic review with quantitative synthesis 
Bergemann, 2009 177 Nether a meta-analysis or systematic review with quantitative synthesis 
Taylor, 2008 178 Nether a meta-analysis or systematic review with quantitative synthesis 
Sterke, 2008 179 Nether a meta-analysis or systematic review with quantitative synthesis 
O'Brien, 2008 180 Insufficient or inadequate data for quantitative synthesis provided  
Loke, 2008 181 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Kongkaew, 2008 182 Nether a meta-analysis or systematic review with quantitative synthesis 
Bond, 2008 183 Not a meta-analysis or systematic review of observational studies 
Takkouche, 2007 184 Insufficient or inadequate data for quantitative synthesis provided  
Howard, 2007 185 Nether a meta-analysis or systematic review with quantitative synthesis 
Hartikainen, 2007 186 Nether a meta-analysis or systematic review with quantitative synthesis 
Bellantuono, 2007 187 Nether a meta-analysis or systematic review with quantitative synthesis 
Bar-Oz, 2007 188 Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
Swenson, 2006 189 Not a meta-analysis or systematic review of observational studies 
Sala, 2006 190 Nether a meta-analysis or systematic review with quantitative synthesis 
Rahimi, 2006  191  Overlapping meta-analysis or systematic review of association of antidepressants and risk of adverse health outcomes 
McIntyre, 2006 192 Nether a meta-analysis or systematic review with quantitative synthesis 
McClintock, 2006 193 Nether a meta-analysis or systematic review with quantitative synthesis 
Hall, 2006 194 Nether a meta-analysis or systematic review with quantitative synthesis 
Lattimore, 2005 195 Insufficient or inadequate data for quantitative synthesis provided  
Gentile, 2005 196 Nether a meta-analysis or systematic review with quantitative synthesis 
Einarson, 2005 197 Insufficient or inadequate data for quantitative synthesis provided  
Wen, 2004 198 Nether a meta-analysis or systematic review with quantitative synthesis 
Weissman, 2004 199 Nether a meta-analysis or systematic review with quantitative synthesis 
Ramasubbu, 2004 200 Nether a meta-analysis or systematic review with quantitative synthesis 
Newman, 2004 201 Nether a meta-analysis or systematic review with quantitative synthesis 
McIntosh, 2004 202 Nether a meta-analysis or systematic review with quantitative synthesis 
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Bailey, 2004 203 Insufficient or inadequate data for quantitative synthesis provided 
Weinrieb, 2003 204 Nether a meta-analysis or systematic review with quantitative synthesis 
Addis, 2000 205 Insufficient or inadequate data for quantitative synthesis provided  
Thase, 1998 206 Nether a meta-analysis or systematic review with quantitative synthesis 
Wilens, 1996 207 Nether a meta-analysis or systematic review with quantitative synthesis 
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eTable 2 Characteristics of meta-analyses of observational studies studying the association between antidepressants and risk of any adverse 
health outcome  
 
Study  
(see references 38-81 in 


















Masarwa, 2019  Case-control 
and cohort 
Persistent pulmonary 
hypertension of the newborn  
SSRIs+SNRIs No SSRIs+SNRIs 
use 
2 (19) Pregnant women (any 
trimester) 
9 (4-16) Moderate 
Halvorsen, 2019  Case-control 
and cohort 
Autism spectrum disorders, 
attention-deficit hyperactivity 
disorder and mental 
retardation in children 
SSRIs No SSRIs use 3 (16) Pregnant women (any 
trimester) 
12 (4-19) Moderate 
Wang, 2018  Case-control 
and cohort 
Dementia  SSRIs; TCAs; 
MAOIs 
No ADs use 3 (11) Elderly patients with 
various disorders 
10 (8-14) Moderate 
Schweiger, 2018  Case-control 
and cohort 




Khanassov, 2018  Case-control 
and cohort 
Osteoporotic fractures  SSRIs No SSRIs 1 (24) General population of 
adults and older adults   
15 (2-29) Moderate 
Jiang, 2018  Cohort Attention-deficit 
hyperactivity disorder in 
children  





Gao, 2018  Cohort Congenital malformations in 
infants 
SSRIs No SSRIs use 7 (37) Pregnant women (first 
trimester) 
5 (2-9) Moderate 
Guan, 2018  Case-control 
and cohort  
Gestational hypertension 
and/or preeclampsia 





Chappuis, 2018  Cohort Dental implant failure SSRIs No SSRIs use 1 (2) General adult 
population 
4 (2-6) Moderate 
Na, 2018  Case-control GI bleeding; any other type 
of bleeding; both GI and any 






5 (20) Patients with a 
diagnosis of abnormal 
bleeding; warfarin 




(see references 38-81 in 




















Man, 2018  Case-control 
and cohort 
Attention-deficit 
hyperactivity disorder in 
children  




8 (7-9) Moderate 
Fu, 2018  Nested case-
control and 
case-control  
Cataract risk SSRIs; SNRIs; 
TCAs 
No ADs use 3 (13) Patients with 
medical/psychiatric 
diagnoses 
5 (3-10) Moderate 
Eckersley, 2018  Cohort Bleeding; mortality SSRIs No SSRIs use 4 (14) Patients undergoing 
coronary artery bypass 
graft surgery  
13 (9-16) Moderate 
Zhou, 2018  Case-control 
and cohort 
Autism spectrum disorders  Any AD No ADs use 1 (13) Pregnant women (any 
trimester) 
8 (3-11) Low 
Morales, 2018  Case-control 
and cohort 
Autism spectrum disorders  Any AD No ADs use 2 (13) Women with pre-
conception exposure 
to antidepressants  
8 (3-11) Moderate 
Andalib, 2017  Case-control 
and cohort 
Autism spectrum disorders SSRIs No SSRIs use 1 (7) Pregnant women (any 
trimester) 
7 (3-11)  Moderate 
Zhang, 2017  Cohort  Cardiovascular-related 
malformations of infants; 
Both atrial and ventricular 
septal defect  
SSRIs No SSRIs use 2 (37) Pregnant women (first 
trimester) 
6 (0-13) Low 
Shen, 2017  Cohort  Cardiovascular-related 
malformations of infants 
Sertraline  No sertraline or 
any other AD use 
6 (40) Pregnant women (first 
trimester) 
6 (0-9) Moderate 
Laporte, 2017  Case-control 
and cohort  
Severe bleeding at any site SSRIs; S 
NRIs 
No AD; No SSRI; 
Other AD; Neither 
SSRI nor NSAID 
1 (44) Patients with a 
diagnosis of abnormal 




(see references 38-81 in 




















Gao, 2017  Cohort Congenital malformations in 
infants 
Fluoxetine  No ADs or 
teratogens use 
8 (38) Pregnant women (first 
trimester) 
5 (2-9) Moderate 
Biffi, 2017  Case-control 
and cohort 
Onset of acute heart disease; 
Cerebrovascular disease 
SSRIs; TCAs; Any 
other AD 
No ADs use 4 (31)  Patients with 
depression 
9 (0-16) Moderate 




Postpartum hemorrhage SSRIs; Any other 
non-SSRIs use 
No ADs use 1 (17) Pregnant women 
(any trimester) 
13 (7-22) Low 
Healy, 2016  Cohort Neurodevelopmental 
delay/spectrum disorders  
SSRI No SSRIs 1 (17) Pregnant women 
(any trimester) 
NR Moderate 
Eke, 2016  Cohort Preterm birth; respiratory 
distress syndrome 
SSRIs No SSRIs 3 (16) Pregnant women  
(first and third 
trimester) 
1.5 (0-5) Moderate 
Bérard, 2016  Case-control 
and cohort 
Major cardiac malformations Paroxetine   No paroxetine use 
or no any other 
ADs use 
6 (87) Pregnant women (first 
trimester) 
6 (1-15) Moderate 
Undela, 2015  Case-control 
and cohort 
Myocardial infarction TCAs; SSRIs; Any 
other AD 
No ADs use 1 (21) Patients with 
depression 
10 (2-18) Moderate 
Singh, 2015 Cohort Perioperative bleeding 
outcomes and/or any cause 
mortality 
SSRIs+SNRIs; 
Any other ADs 
No SSRIs+SNRIs 
use or no any other 
ADs use 
4 (19) Pre-operative patients 8.6 (1-16) Low 
Jiang, 2015  Case-control 
and cohort 




No ADs use only 2 (30) Patients with various 
disorders with a 
diagnosis of UGIB 




(see references 38-81 in 























SSRIs No SSRIs  3 (23) Patients with 
depression 
13 (4-31) Low  
Huang, 2014  Case-control 
and cohort  
Low birth weight; Preterm 
birth 
SSRIs; Any other 
non-SSRIs use 
No ADs use 2 (43) Pregnant women (any 
trimester) 
NR Moderate 
Huybrechts, 2014  Case-control 
and cohort 
Spontaneous abortion SSIRs No SSRIs 2 (20) Pregnant women 
(early and late 
pregnancy) 
NR Moderate 
Grigoriadis, 2014  Case-control 
and cohort 
Pulmonary hypertension of 
the newborn 
SSRIs No SSRIs or no 
any other ADs use 
1 (3) Pregnant women with 
(early pregnancy) 
7 (4-10) Moderate 
Oh, 2014  Case-control 
and cohort 
Coronary heart disease TCAs No TCAs 1 (14) General population of 
adults   
NR Moderate 
Wu, 2013  Case-control 
and cohort 
Osteoporotic fractures  TCAs No TCAs 1 (12) General population of 
older adults   
12 (2-30) Moderate 
Ross, 2013  Cohort Gestational age; APGAR 
score  
TCAs; SSRIs; Any 
other AD 
No ADs use 3 (42) Pregnant women (any 
trimester) 
3 (0-21) Moderate 
Riggin, 2013 Cohort Congenital malformations in 
infants 
Fluoxetine  No fluoxetine or 
teratogens use   
2 (38) Pregnant women (first 
trimester) 
NR Moderate 
Grigoriadis, 2013  Case-control 
and cohort 






No ADs use 3 (21) Pregnant women (any 
trimester) 
5 (4-7) Moderate 
Myles, 2013  Case-control 
and cohort 
Major malformations in 
infants 
Citalopram  No ADs use 2 (13) Pregnant women (first 
trimester) 
NR High quality 
Nikfar, 2012  Case-control 
and cohort 
Major malformations in 
infants; Spontaneous abortion 
SSRIs No SSRIs  2 (28) Pregnant women (any 
trimester) 
NR Low 
Oderda, 2012  Case-control 
and cohort 
Hip Fracture  Any AD No ADs use 1 (18) General population of 
older adults   
5 (0-19) Critically 
Low 
Eom, 2012  Case-control 
and cohort 
Breast cancer Any AD No ADs use 1 (18) General population of 
adults 




(see references 38-81 in 


















Lee, 2012  Case-control 
and cohort 
Colon cancer SSRIs No SSRIs or no 
any other ADs use 
1 (6) General population of 
adults and older adults  
6 (2-7) Moderate 
Cosgrove, 2011  Case-control 
and cohort 
Breast and ovarian cancer SSRIs; TCAs No ADs use 2 (32) General population of 
adults  
NR Low  
Barbui, 2009  Case-control 
and cohort 
Suicide attempt and 
completion 
SSRIs No SSRIs 3 (14) Patients with major 
depressive disorders 
6 (4-8) High quality 
Hemels, 2005  Cohort Spontaneous abortion Any AD No ADs use 1 (11) Pregnant women (any 
trimester) 
NR Moderate 
AD-antidepressants, AMSTAR2 – acronym of A Measurement Tool to Assess systematic Reviews, version 2, BMD – bone mineral density, APGAR – acronym of Appearance 
(skin color), Pulse (heart rate), Grimace (reflex irritability), Activity (muscle tone), and Respiration, GI – gastrointestinal, NR– non reported, RCTs – randomized controlled trials, 
SNRIs – serotonin–norepinephrine reuptake inhibitors, SARIs – serotonin antagonist and reuptake inhibitors, SSRIs – selective serotonin reuptake inhibitors, TCAs – tricyclic 











eTable 3 Suggestive evidence (Class III) for the association of antidepressant use and risk of adverse health outcomes in meta-analyses of 
observational studies 
     Criteria used for classification of level of evidence 












I2 (p) PI (95% 
CI) 
SSE/ESB LS CE 
Pulmonary hypertension 
(pregnancy maternal exposure; 
Masarwa, 2019) 
SSRI or SNRI users/  
No SSRI or SNRI users 







7 080 850 
3.6x10-4 72 (<0.000) 0.73-4.56 No/NP Yes III 
Pulmonary hypertension  
(late pregnancy exposure; 
Masarwa, 2019) 
SSRI or SNRI users/  
No SSRI or SNRI users 







5 979 785 
9.2x10-5 76 (<0.000) 0.77-5.68 No/No Yes III 
Autism spectrum disorders 
(Halvorsen, 2019) 
SSRI users/  
No SSRI users 






1 2682 40 




SSRI users/  
No SSRI users 






1 179 596 
2.3x10-4 56 (0.061) 0.82-2.37 No/NP Yes III 
Attention-deficit hyperactivity 
disorder in children 
(Jiang, 2018) 
Prenatal exposure to 
ADs/ No AD users 
6 RR, 1.34 
(1.14,1.57) 
Increased 
risk for ADs 
56 272/ 
2 840 554 
3.3x10-4 79 (<0.000) 0.81–2.21 No/NP Yes  III 
Attention-deficit hyperactivity 
disorder in children  
(2+3 trimester; Jiang, 2018) 
Prenatal exposure to 
ADs/ No AD users 
5 RR, 1.37 
(1.17,1.60) 
Increased 
risk for ADs 
41 564/ 
2 281 198 
6.9x10-5 0 (0.754) 1.06-1.76 No/NP Yes III 
Attention-deficit 




exposure to ADs/ 
Non-AD users 











no users of any other 
AD 






1 955 042 
 




Any SSRI users/ 
Non-SSRI users 






7 368 339 
2.1x10-5 54 (0.003) 0.92-1.72 No/NP Yes  III 
            
Both atrial and ventricular 
septal defect 
(Zhang, 2017) 
Any SSRI users/ 
Non-SSRI users 







1.6x10-5 40 (0.041) 0.95-1.71 No/NP Yes  III 
17 
 
Septal defects  
(Gao, 2017) 
Fluoxetine/ No ADs 
or teratogens use 



















1.0x10-5 14 (0.332) 1.02-1.55 No/No Yes  III 
Preterm birth 
(unadjusted estimates; 
 Eke, 2016) 
SSRIs/  
Non-SSRIs users 






1 307 761 
 














2.6x10-4 83 (<0.000) 0.83-2.12 Yes/Yes  Yes  III 










2 169 318 




paroxetine use  







2.3x10-5 0 (0.653) 1.09-1.49 No/NP No III 

























1.2x10-5 90 (<0.000) 0.70-5.38 No/NP Yes  III 
Low birth weight 
(Huang, 2014) 
 
Any AD users/ Non-
AD users 







2.8x10-5 61 (0.001) 0.88-2.32 No/NP Yes  III 
Preterm birth during late 
pregnancy 
(Huybrechts, 2015) 
Any AD users/ Non-
AD users 







2.4X10-13 83 (<0.000) 1.09-2.37 Yes/NP Yes III 
Gestational age 
(Ross, 2013) 
Any AD users/ Non-
AD users 







3.9x10-5 71 (<0.000) -0.81, 0.36 No/Yes Yes  III 
RBC–red blood cells, AD– antidepressants, TCAs – tricyclic antidepressants, SSRIs – selective serotonin reuptake inhibitors, SNRIs – serotonin–norepinephrine reuptake 
inhibitors, n – number of included studies per association, ES – effect size, N – number of cases, I2 –heterogeneity, PI – prediction interval, CI – confidence interval, SSE – small-
study effect, ESB –excess significance bias, LS – largest study with significant effect, CE – class of evidence, OR – odds ratio, RR – relative risk, SMD  – standardized mean 




eTable 4 Weak evidence (Class IV) for the association of antidepressant use and risk of adverse health outcomes in meta-analyses of 
observational studies 
 
     Criteria used for classification of level of evidence 












I2 (p) PI (95% CI) SSE/ESB LS CE 
Mental retardation  
(Halvorsen, 2019) 
SSRI users/  
No SSRI users 






0.030 0 (0.718) NA NA/NA No  IV 
Dementia 
(Wang, 2018) 
SSRI users/  
No SSRI users 








0.037 98 (<0.000) 0.23–13.49 No/NA Yes IV 
Dementia 
(Wang, 2018) 
TCA users/  
No SSRI users 






2.1x10-4 96 (<0.000) 0.34-13.54 No/NA Yes IV 
Dementia 
(Wang, 2018) 
MAOI users/  
No MAOI users 






0.033 80 (0.025) NA NA/NA Yes IV 
Attention-deficit hyperactivity 
disorder  
(first trimester; Jiang, 2018) 
Prenatal exposure to 
ADs/ No AD users 








0.047 91 (<0.000) 0.41–4.01 No/NP Yes  IV 
Attention-deficit hyperactivity 




exposure versus no 
exposure 






0.007 60 (0.083) 0.13-13.88 No/NA Yes IV 
Attention-deficit hyperactivity 
disorder in children  
(Jiang, 2018) 
SSRIs /  
Non-SSRIs users  






0.001 86 (<0.000) 0.72-2.51 No/NA  Yes  IV 
Attention-deficit hyperactivity 











1.2x10-4 0 (0.790) 1.12-1.99 No/NA Yes IV 
Gestational hypertension or 
preeclampsia 
(Guan, 2018) 
SSRI users/  
No SSRI users 






0.007 71 (0.002) 0.81-1.82 Yes/Yes No IV 
Atrial septal defects 
(Gao, 2018) 
Any SSRI users/  
Non-SSRI users 






0.003 72 (0.002) 0.53-6.31 No/Yes No  IV 
Septal defects 
(Gao, 2018) 
Any SSRI users/  
Non-SSRI users 






0.050 67 (0.009) 0.50-3.80 No/NP Yes IV 
Right ventricular outflow tract 
defects 
Any SSRI users/  
Non-SSRI users 












SSRI users/  
No SSRI users 






0.048 6 (0.365) 0.79-1.64 No/NP No IV 
Dental implant failure 
(Chappuis, 2018) 
SSRI users/  
No SSRI users 






9.8x10-5 0 (0.770) NA NA/No Yes  IV 











0.043 0 (0.593) 0.83-1.65 No/NP No  IV 
Cataract development 
(Fu, 2018) 
SNRIs/ non-users or 
no users of any other 
AD 







0.006 68 (0.026) 0.79-1.63 Yes/No  Yes  IV 
Autism spectrum disorders 
(Zhou, 2018) 
Any AD users/ Non-
AD users 













sertraline users  







0.015 64 (0.001) 0.66-2.79 No/NP Yes  IV 
Non-septal defects 
(Gao, 2017) 
Fluoxetine/ No ADs 
or teratogens use 







0.003 7 (0.374) 0.98-1.97 No/NP Yes  IV 











0.001 73 (0.026) 0.31-4.96 No/NP Yes  IV 
Major malformations 
(Bérard, 2016) 
Paroxetine/ No any 
other SSRIs use 







0.003 0 (0.712) 1.05-1.35 No/NP No  IV 
Major malformations 
(Bérard, 2016) 
Paroxetine/ No any 
other ADs use  











other SSRIs use  







0.001 0 (0.596) 1.08-1.49 No/NP No  IV 
Cardiac malformations 
(Bérard, 2016) 
Paroxetine/ No any 
other ADs use 







0.006 1 (0.436) 1.03-1.48 No/NP No  IV 
Autistic Spectrum or 
related Disorders  
(Healy, 2016) 
SSRIs / Non-SSRIs 
users 







0.001 91 (<0.000) 0.42-9.02 No/NP Yes  IV 
Ischemic stroke 
(Shin, 2014) 
SSRIs / Non-SSRIs 
users 












SSRIs / Non-SSRIs 
users 







0.033 75 (<0.000) 0.57-3.07 No/NP Yes  IV 
All types of stroke 
(Shin, 2014) 
SSRIs / Non-SSRIs 
users 







0.008 93 (<0.000) 0.57-3.44 No/Yes Yes  IV 











0.019 97 (<0.000) 0.41-5.56 No/NP Yes  IV 
Apgar score at 1 minute 
(Ross, 2013) 
















teratogens users   







2.4x10-6 1 (0.441) 1.27-2.02 No/NP No IV 
Poor neonatal adaptation 
(Grigoriadis, 2013) 
 
Any AD users/ Non-
AD users 




risk for ADs 
75/ 
986 
7.8x10-13 0 (0.617) 2.91-8.81 No/No Yes  IV 
Respiratory distress syndrome 
(Grigoriadis, 2013) 
Any AD users/  
No AD users  






1.3x10-15 38 (0.115) 1.43-3.37 Yes/Yes Yes 
 
IV 
Tremors   
(Grigoriadis, 2013) 
Any AD users/ Non-
AD users 





risk for ADs 
60/ 
482 
2.7x10-6 45 (0.144) 0.35-177.44 No/Yes Yes  IV 
Major malformations 
(Nikfar, 2013) 
SSRIs / Non-SSRIs 
users 







0.002 25 (0.146) 0.91-1.68 Yes/No No IV 
Spontaneous abortion 
(Nikfar, 2013) 
SSRIs / Non-SSRIs 
users 







9.6x10-6 3 (0.403) 1.25-2.74 No/No No  IV 
Breast and ovarian cancer 
(Cosgrove, 2011) 
SSRIs / Non-SSRIs 
users 







0.010 15 (0.287) 0.98-1.14 Yes/No No IV 
Suicide attempt and 
completion in adults  
(Barbui, 2009) 
SSRIs / Non-SSRIs 
users 







4.1x10-9 0 (0.555) NA NA/NP No  IV 
Spontaneous abortion 
(Hemels, 2005) 
Any AD users/ Non-
AD users 
11 OR, 1.46 
(1.19, 1.79) 
Increased 
risk for ADs 
373/ 
3194 
2.8x10-3 0 (0.981) 1.15-1.85 No/NP No  IV 
AD–antidepressants, APGAR – backronym of Appearance (skin color), Pulse (heart rate), Grimace (reflex irritability), Activity (muscle tone), and Respiration, TCAs – tricyclic 
antidepressants, SSRIs – selective serotonin reuptake inhibitors, SNRIs – serotonin–norepinephrine reuptake inhibitors, n – number of included studies per association, ES – effect 
size, N – number of cases, I2 –heterogeneity, PI – prediction interval, CI – confidence interval, SSE – small-study effect, ESB –excess significance bias, LS – largest study with 
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eTable 5 No evidence (Non-significant associations, p>0.05) for the association of antidepressant use and risk of adverse health outcomes in 
meta-analyses of observational studies 
 
     Criteria used for classification of level of evidence 











I2 (p) PI (95% CI) SSE/ES
B 
LS CE 




with SSRI exposure 
versus no exposure 











disorder with SSRI 
exposure versus no 
exposure 







0.489 34 (0.182) 0.71-1.60 No/NP No  NS 
Left ventricular outflow tract 
defects 
(Gao, 2018) 
SSRIs /  
Non-SSRIs users 







0.616 0 (0.892) 0.17-6.99 No/NP No  NS 
Ventricular septal defect 
(Gao, 2018) 
SSRIs /  
Non-SSRIs users 







0.232 36 (0.140) 0.76-1.60 NA/NP  Yes NS 
BMD Lumbar Spine 
(Schweiger, 2018) 
SSRIs /  
Non-SSRIs users 







0.897 71 (0.065) NA NA/No  Yes NS 












0.786 0 (0.545) NA NA/NP No  NS 
BMD Total Hip 
(Schweiger, 2018) 
SSRIs /  
Non-SSRIs users 







0.677 98 (<0.000) NA NA/No Yes NS 











0.719 0 (0.644) NA NA/NP No NS 
Attention-deficit hyperactivity 













0.714 0 (0.524) 
 
NA NA/NA No NS 
Attention-deficit hyperactivity 
disorder in children  
(Jiang, 2018) 












SSRI users/  
No SSRI users 







0.071 83 (<0.000) 0.47-3.70 No/No No 
 
NS 
GI bleeding  
(Na, 2018)  







0.689  0 (0.806) 0.75 -1.41 No/NP No NS 
Any other type of bleeding  
(Na, 2018) 








0.443 0 (0.886) 0.15-5.24 No/NP No NS 
Both GI and any other type 
of bleeding 
(Na, 2018) 








0.766 6 (0.371) 0.77-1.25 No/NP  No NS 



























0.754 60 (0.083) 0.06-14.93 No/NP No NS 












0.418 5 (0.349) 0.26-3.28 No/NP No  NS 

























0.664 0 (0.814) 0.84-1.26 No/NP No  NS 
Autism spectrum disorders 
(Morales, 2018) 
Any AD users/ 
Non-AD users with 
a history of 
affective disorder 







0.192 51 (0.069) 0.58 -2.40 No/NP No  NS 








of risk  
416/ 
1975394 
















0.407 0 (0.805) 0.56-2.68 No/NP No NS 












0.902 32 (0.219) 0.02-56.42 No/NP No NS 












0.869 0 (0.755) 0.67-1.59 Yes/NP No NS 
















Fluoxetine/ No ADs 
or teratogens use 








0.219 0 (0.526) 0.05-34.60 No/NP No NS 
Eye malformations  
(Gao, 2017) 
Fluoxetine/ No ADs 
or teratogens use 







0.564 0 (0.399) 0.00-420.44 No/NP No NS 
Urogenital malformations 
(Gao, 2017) 
Fluoxetine/ No ADs 
or teratogens use 








0.932 39 (0.159) 0.00-3.50 No/NP Yes NS 
Digestive malformations 
(Gao, 2017) 
Fluoxetine/ No ADs 
or teratogens use 








0.800 0 (0.861) 0.02-51.29 No/NP No NS 
Respiratory malformations 
(Gao, 2017) 
Fluoxetine/ No ADs 
or teratogens use 












Fluoxetine/ No ADs 
or teratogens use 








0.322 0 (0.726) 0.34-1.98 Yes/NP No  NS 
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Acute heart disease 
(Biffi, 2017) 
Any AD users/ 
Non-AD users 








0.138 92 (<0.000) 0.35-5.19 No/NP Yes  NS 

























0.239 0 (0.745) 0.85-1.32 No/NP No NS 
Preterm birth 
(Huybrechts, 2015) 
Any AD users in 
early pregnancy/ 
Non-AD users 







0.127 85 (<0.000) 0.64-2.07 No/NP Yes  NS 
Myocardial infarction 
(Undela, 2015) 
Any AD users/ 
Non-AD users 








0.687 98 (<0.000) 0.51-2.08 No/NP Yes  NS 
Requirement of reoperation 

























0.343 76 (0.002) 0.46-2.88 No/No Yes NS 
Requirement of RBC 
transfusion 
(Singh, 2015) 
Any other AD 
users/ Non-any 
other AD users 








0.874 0 (0.790) 0.12-8.88 No/NP No  NS 
Pulmonary hypertension of 
the newborn 
(Grigoriadis, 2014) 





























first trimester / 
Non-AD users  


















NR/NR 0.254 0 (0.858) 0.89-1.21 No/NA No  NS 
Breast cancer 
(Eom, 2012) 










0.574 36 (0.063) 0.87-1.18 Yes/NP No  NS 
Colon cancer 
(Lee, 2012) 
SSRIs / Non-SSRIs 
users or any other 
ADs 







0.071 41 (0.131) 0.66-1.21 No/No No  NS 
Breast and ovarian cancer  
(Cosgrove, 2011) 








0.251 47 (0.021) 0.88-1.22 No/NP No NS 
GI – gastrointestinal, RBC–red blood cells, FFP– fresh frozen plasma, BMD – bone mineral density, AD– antidepressants, TCAs – tricyclic antidepressants, SSRIs – selective 
serotonin reuptake inhibitors, SNRIs – serotonin–norepinephrine reuptake inhibitors, SADs– serotoninergic antidepressants, n – number of included studies per association, ES – 
effect size, N – number of cases, I2 –heterogeneity, PI – prediction interval, CI – confidence interval, SSE – small-study effect, ESB –excess significance bias, LS – largest study 
with significant effect, CE – class of evidence, CES= OR – odds ratio, RR – relative risk, HR– hazard ratio, SMD – standardized mean difference, NA– not applicable, NP – not 




















Supplementary methods  
Selection between overlapping meta-analysis 
At full-text assessment, we extracted relevant information to define antidepressants exposure, 
inclusion criteria for the population of interest and outcome definition of each meta-analysis. When 
two or more meta-analyses focused on the same combination of exposure, population, and outcome 
we selected only the meta-analysis that included the largest data set and sufficient individual data 
for statistical analysis.208 We also examined whether the main reported conclusions were 
concordant regarding the direction and the significance level of the association.2 If the results were 
concordant, then again, we selected the one that included the largest data set and sufficient 
individual data for statistical analysis.208If two or more meta-analyses focused on the same 
combination of exposure, population, and outcome, but included a different set of primary studies 
(for example, different set of cohort studies but the same set of case-control studies and vice versa, 
or only cohort studies) then we kept both or all. If two or more meta-analyses focused on the same 
combination of exposure, population, and outcome and included exactly the same number and set 
of included studies then we kept the most recent one.209 We adopted this procedure not only to 
avoid overlapping data sets as much as possible, but also not to miss as much any valuable 
information. We also examined the concordance between selected and non-selected meta-analyses 
by sensitivity analysis limited to non-selected associations due to overlap (eTable 6).210 
Quality assessment  
AMSTAR 2 211 assesses whether included meta-analyses clearly defined the research question and 
inclusion criteria, mentioned an a-priori protocol, explained inclusion criteria, conducted a 
comprehensive literature search, screened literature and extracted data in duplicate, provided a list 
of excluded studies with reason for exclusion, described included studies in detail, assessed risk of 
bias of included studies, reported on the source of funding, used appropriate statistical methods, 
accounted for risk of bias for instance with sensitivity analyses, considered risk of bias when 
interpreting results, explained and discussed any heterogeneity in results, assessed and discussed 
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publication bias, reported any potential conflict of interest. Based on the above listed items, 
AMSTAR 2 defines a systematic review’s quality as high, moderate, low, or critically low. 
Compared with AMSTAR, AMSTAR 2 also assesses the quality of the studies included in a meta-
analysis, without limiting the quality assessment to the technical aspects of the meta-analysis itself. 
Additionally, compared to ROBIS, AMSTAR has much better agreement among raters.212 
Grading method 
We assessed the credibility of the evidence using established criteria published in several umbrella 
reviews.208,209,210 Specifically, associations had the strongest validity and were not suggestive of 
bias (Class I: convincing) whenever they met all the following criteria: had >1000 cases; had p-
value <10-6 based on random-effects meta-analysis; had no evidence of small-study effects and 
excess significance; had 95% prediction interval (PI) that excluded the null value; the largest study 
had a nominally significant effect (p<0.05); and  had low or moderate between-study heterogeneity 
(I² <50%). Highly suggestive evidence (Class II) required >1000 cases; had p-value <10-6 based on 
random-effects meta-analysis; and the largest study had a nominally significant effect (p<0.05). 
Suggestive evidence (Class III) criteria required only >1000 cases and had p-value <10-3 based on 
random-effects meta-analysis. Weak evidence (Class IV) criteria required only all other remained 
associations with a p-value ≤0.05. These criteria have been proven to provide a systematic and 
transparent judgment of the methodological flaws that can occur in various meta-analyses. It is well 
known, that heterogeneity, publication bias, small-study effects, selective reporting, and excess of 
significant bias in the published meta-analyses can contribute to biased results of a meta-analyses. 
Thus, this method appears to be more objective than other quality grading methods because it uses 
several statistical tests to assess different type of bias and it can work for many types of research 
questions.213 Notably, an empirical evaluation of different grading approaches concluded that 




Sensitivity analysis results of convincing and highly suggestive evidence associations from the main 
analysis 
Cohort studies (both prospective and retrospective) 
A sensitivity analysis limited to cohort studies showed that none of the associations within class I 
retained the same rank (Table 3). However, this analysis showed that six associations were 
supported by highly suggestive evidence (Table 3). These included the increased risk of autism 
during pregnancy, osteoporotic fractures, pre-term birth and lower APGAR scores at 5 minutes 
(antidepressants during pregnancy), and suicide attempt/completion in children and adolescents, as 
well as the decreased risk of suicide attempt/completion in adults and older adults. 
The associations between antidepressants and attention-deficit hyperactivity disorder in children, 
postpartum haemorrhage, and osteoporotic fractures (TCAs) were downgraded to suggestive 
evidence, while the associations between antidepressants and ASD during pre-pregnancy, severe 
bleeding, upper gastrointestinal bleeding, and hip fracture were downgraded to weak evidence. 
Prospective cohort studies 
A sensitivity analysis limited to prospective cohort studies showed that none of the associations 
within class I retained the same rank (Table 3). The most important change was for highly 
suggestive associations, with one being upgraded to convincing evidence (preterm birth related to 
any antidepressant use), while all other were downgraded to lower ranks of evidence. More 
analytically, the associations between antidepressants and attention-deficit hyperactivity disorder in 
children, and postpartum haemorrhage were downgraded to suggestive evidence, while the 
associations with severe bleeding and Apgar score at 5 minutes were downgraded to weak 
evidence. Finally, the association with autism during pre-pregnancy turned into non-significant.  
Studies adjusted for multiple covariates  
When the sensitivity analysis was limited to studies adjusted for multiple potential confounders 
beyond age and sex (as described in eTable 7 in the Supplement), the association with suicide risk 
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in children and adolescents, the association between any antidepressant and ASD during pre-
pregnancy remained at convincing evidence, while five more associations remained at highly 
suggestive evidence as in the main analysis (Table 5). These included, increased risk of attention-
deficit hyperactivity disorder in children, osteoporotic fractures (SSRIs and TCAs), hip fracture 
(any antidepressant), and upper gastrointestinal bleeding. The positive associations with cataract 
development, severe bleeding, and postpartum haemorrhage were downgraded to suggestive 
evidence as well as the protective association with suicide risk in adults, whereas the association 
with preterm birth, and Apgar score at 5 minutes were downgraded to weak evidence. Finally, the 
association with autism during pregnancy included only unadjusted estimates and excluded from 
this analysis. 
Confounding by indication  
This analysis included only adjusted studies that were controlled/matched for a psychiatric 
condition as depicted in eTable 7 in the Supplement. This analysis showed that none of the 
associations within class I retained the same rank (Table 3). The association with autism during pre-
pregnancy was downgraded to highly suggestive, while the association with suicide 
attempt/completion in children and adolescents was downgraded to weak (Table 4 in the main text). 
Two more associations, i.e., osteoporotic fractures (SSRIs and TCAs) remained at highly 
suggestive evidence as in main analysis (Table 3). The associations with attention-deficit 
hyperactivity disorder in children, postpartum haemorrhage, and the protective association with 
suicide risk in adults, were downgraded to suggestive evidence, while the association with preterm 
birth was downgraded to weak evidence. 
High-quality primary studies 
This analysis limited to high-quality primary studies that had a Newcastle-Ottawa Scale (NOS) 
score bigger than seven (or defined as such by using other instruments) as reported from the 
original meta-analyses’ authors. This analysis showed that the three associations within class I 
retained the same rank (Table 3). These included the increased risk of autism before and during 
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pregnancy, and suicide attempt and completion in children and adolescents. Seven more 
associations remained at highly suggestive evidence as in main analysis (Table 3). These included 
the attention-deficit hyperactivity disorder in children, osteoporotic fractures (SSRIs and TCAs), 
hip fracture (any antidepressant), postpartum haemorrhage, preterm birth, and the protective 
association with suicide risk in adults. The remaining associations with cataract development, 
severe bleeding, upper gastrointestinal bleeding, and Apgar score at 5 minutes were downgraded to 
weak evidence.  
Classes of antidepressants 
A sensitivity analysis limited to SSRIs showed that the associations with increased suicide risk in 
children and adolescents and autism during pregnancy remained convincing, while another one was 
upgraded to convincing evidence (lower APGAR scores at 5 minutes). Three more associations 
were supported by highly suggestive evidence (Table 3). These included the osteoporotic fractures, 
preterm birth, and the protective association with suicide risk in adults. 
When the sensitivity analysis was limited to TCAs, two associations remained at highly suggestive 
evidence i.e., cataract development and osteoporotic fractures.  
The analysis limited to other or mixed antidepressants showed that the association between any 
antidepressant and autism during pre-pregnancy remained convincing, one association was 
upgraded to convincing evidence (preterm birth), while one was downgraded to suggestive 
evidence (attention-deficit hyperactivity disorder in children). Another one turned into non-
significant, i.e, APGAR scores at 5 minutes. Finally, three other associations remained at highly 
suggestive evidence (Table3). These included severe bleeding, postpartum haemorrhage, and upper 
gastrointestinal bleeding. 
Studies located in Europe 
When the sensitivity analysis was limited to studies located in Europe, the association between 
SSRIs and autism during pregnancy remained at convincing evidence (Table3), while the 
association with suicide attempt/completion in children and adolescents was downgraded to weak 
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evidence. Five associations remained at highly suggestive evidence (upper gastrointestinal 
bleeding, preterm birth, osteoporotic fractures (SSRIs and TCAs), and hip fractures (either TCAs or 
SSRIs). The association with severe bleeding and the protective association with suicide risk in 
adults were downgraded to suggestive evidence, while the associations with attention-deficit 
hyperactivity disorder in children and Apgar score at 5 minutes were downgraded to weak 
evidence.  
Studies located in North America 
When the sensitivity analysis was limited to studies located in North America i.e.., USA and 
Canada, none of the associations within class I retained the same rank (Table 3). Four more 
associations i.e., osteoporotic fractures (SSRIs and TCAs), hip fractures (either TCAs or SSRIs), 
and preterm birth remained at highly suggestive evidence as in main analysis (Table 4 in the main 
text). The associations with autism during pregnancy and severe bleeding were downgraded to 
suggestive evidence, while the associations with autism before pregnancy, suicide 
attempt/completion in children and adolescents, attention-deficit hyperactivity disorder in children, 
postpartum haemorrhage, upper gastrointestinal bleeding, Apgar score at 5 minutes, and the 
protective association with suicide risk in adults were downgraded to weak evidence.  
Studies located in other regions 
When the sensitivity analysis was limited to studies located in other regions, none of the 
associations within class I and II retained the same rank (Table3). The associations with postpartum 
haemorrhage, upper gastrointestinal bleeding, preterm birth, and hip fracture (either TCAs or 
SSRIs) were downgraded to weak evidence, while the association with severe bleeding turned into 
non-significant. For the remaining associations within Class I and II there were no available data. 
Sensitivity analysis results of non-selected meta-analyses due to overlap  
The results from this analysis are presented in eTable 6. Among the 74 associations, that were 
overlapped between selected and non-selected meta-analyses with adequate data, only three (4.1%) 
had convincing evidence; the association between any antidepressant before pregnancy and 
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SSRI/any antidepressant during pregnancy and autism spectrum disorders (ASD).29, 84, 215 Three 
more associations (4.1%) were supported by highly suggestive evidence. These included the 
association between SSRI before pregnancy and autism spectrum disorders and osteoporotic 
fractures.57, 137,151, 13 There was suggestive evidence for eight further associations (10.8%) linked to 
increased risk of adverse health outcomes. For the rest of the associations, there was either weak 
(n=32 [43.2%]) or no evidence (n=28 [37.8%]; all associations with p>0.05). Overall, we found an 

















eTable 6 Sensitivity analysis results of non-selected meta-analyses due to overlap 
 

















































OR 1.94 (1.37, 2.76) 2.1x10-3 0.79 (0.08, 7.84) 88 0.95 0.70, 5.39 Weak 





100 /  
36925 
2 Cohort OR 1.81 (1.44, 2.29) 6.0x10-7 2.02 (1.53, 2.66) 20 0.00 NA Weak 





8040 /  
69219 
4 Case-control OR 1.77 (1.49, 2.09) 3.3x10-11 1.90 (1.50, 2.40) 0 0.98 1.22, 2.56 Convincing  




5040 /  
50187 
3 Case-control OR 1.50 (0.74, 3.03) 0.260 2.18 (1.37, 3.46) 84 0.87 0.00, 7910.38 No association 








OR 1.41 (1.12, 1.78) 0.003 1.46 (1.17, 1.82) 63 0.85 0.72, 2.78 Weak 




4849 /  
772331 
2 Cohort HR 1.26 (0.91, 1.74) 0.160 1.46 (1.17, 1.82) 67 0.00 NA No association 




12469 /  
116925 
5 Case-control OR 1.52 (1.09, 2.13) 0.014 1.9 (1.48, 2.44) 61 0.61 0.52, 4.44 Weak 
Mezzacappa, 2017 Autism spectum 
disorders 
Antidepressant 
during the first 
trimester 




OR 1.55 (1.19, 2.03) 0.001 1.46 (1.17, 1.82) 68 0.78 0.70, 3.44 Weak 
Mezzacappa, 2017 Autism spectum 
disorders 
Antidepressant 
during the first 
trimester 
4849 /  
772331 
2 Cohort HR 1.26 (0.91, 1.74) 0.161 1.46 (1.17, 1.82) 67 0.00 NA No association 
Mezzacappa, 2017 Autism spectum 
disorders 
Antidepressant 
during the first 
trimester 
12469 /  
116925 
5 Case-control OR 1.79 (1.27, 2.52) 1.0x10-3 2.05 (1.58, 2.66) 55 0.76 0.62, 5.13 Suggestive 
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Mezzacappa, 2017 Autism spectum 
disorders 
Antidepressant 
during the second 
trimester 
8040 /  
69219 
4 Case-control OR 1.67 (1.14, 2.45) 0.009 2.30 (1.63, 3.24) 38 0.38 0.44, 6.33 Weak 
Mezzacappa, 2017 Autism spectum 
disorders 
Antidepressant 
during the third 
trimester 
8040 /  
69219 
4 Case-control OR 1.54 (0.82, 2.90) 0.180 2.69 (1.81, 4.00) 73 0.55 0.11, 22.57 No association 





3354 /  
25728 
3 Case-control OR 2.05 (1.20, 3.49) 0.008 1.93 (0.88, 4.24) 0 0.89 0.07, 64.16 Weak 
Kaplan, 2017 Autism spectum 
disorders 
SSRI discontinuation 
until 3 months before 
pregnancy vs. 
unexposed 
3852 /  
652201 
2 Cohort RR 1.31 (0.98, 1.74) 0.065 1.46 (1.17, 1.82) 46 0.00 NA No association 




6890 /  
64569 
3 Case-control OR 1.84 (1.48, 2.28) 2.4x10-8 1.90 (1.50, 2.40) 0 0.78 0.46, 7.35 Highly 
suggestive 




10424 /  
107688 
4 Case-control OR 1.81 (1.47, 2.24) 3.3x10-8 1.80 (1.40, 2.31) 0 0.94 1.14, 2.88 Convincing 








OR 1.45 (1.15, 1.81) 0.002 1.20 (0.90, 1.60) 31 0.18 0.86, 2.43 Weak 




4068 /  
632851 
2 Cohort OR 1.69 (0.80, 3.56) 0.170 1.20 (0.90, 1.60) 82 0.00 NA No association 




6596 /  
355394 
5 Case-control OR 1.38 (1.08, 1.75) 0.009 1.35 (0.94, 1.93) 0 0.38 0.93, 2.03 Weak 




9061 /  
83905 
5 Case-control OR 1.65 (1.23, 2.23) 1.0x10-3 1.90 (1.47, 2.45) 38 0.76 0.73, 3.73 Suggestive 








OR 1.44 (1.12, 1.85) 0.005 1.20 (0.90, 1.60) 24 0.19 0.82, 2.52 Weak 




4849 /  
772427 
2 Cohort RR 1.54 (0.86, 2.75) 0.153 1.20 (0.90, 1.60) 70 0.00 NA No association 




3846 /  
26540 
4 Case-control OR 1.44 (1.02, 2.02) 0.037 1.00 (0.59, 1.68) 7 0.37 0.62, 3.35 Weak 
37 
 




3992 /  
679410 
3 Cohort HR 1.61 (1.16, 2.25) 0.005 1.40 (1.02, 1.92) 46 0.33 0.06, 44.64 Weak 
Kaplan, 2016 Autism spectum 
disorders 
SSRI during the first 
trimester 
7382 /  
65381 
4 Case-control OR 1.91 (1.28, 2.83) 0.001 2.00 (1.54, 2.60) 42 0.98 0.46, 7.91 Weak 
Brown, 2017 Autism spectum 
disorders 
SSRI during the first 
trimester 
3846 /  
26540 
4 Case-control OR 1.75 (1.16, 2.63) 0.007 1.30 (0.72, 2.36) 21 0.64 0.51, 5.95 Weak 
Kaplan, 2016 Autism spectum 
disorders 
SSRI during the 
second trimester 
7382 /  
65381 
4 Case-control OR 1.73 (1.15, 2.61) 0.008 2.30 (1.63, 3.25) 29 0.28 0.46, 6.58 Weak 
Kaplan, 2016 Autism spectum 
disorders 
SSRI during the third 
trimester 
7382 /  
65381 
4 Case-control OR 1.64 (0.83, 3.24) 0.163 2.70 (1.81, 4.03) 68 0.56 0.10, 26.8 No association 






4 Cohort OR 1.22 (0.89,1.67) 0.210 1.60 (1.10, 1.30) 92 0.50 0.31, 4.88 No association 
McDonagh, 2014  Preterm birth Antidepressant 
during pregnancy  




OR  1.84 (0.79, 4.27) 0.155 1.73 (0.63, 4.58) 0 NA NA No association 
Anglin, 2014  Upper 
gastrointestinal 
bleeding 
SSRIs + or NSAIDs  
(Patients with 
various disorders 








OR 1.66 (1.44,1.91) 8.2x10-13 1.06 (0.57, 1.97) 82 0.80 0.93, 2.95 Suggestive 
Painfully, 2013 Cardiovascular 
malformations 
Paroxetine during 
first trimester  
23746/  
1473816 
11 Cohort RR 1.25 (1.01, 1.54) 0.041 1.03 (0.80, 1.33) 30 0.95 0.78, 2.01 Weak 
Grigoriadis, 2013  Major  
malformations 
SSRI during first 





RR 0.93 (0.85, 1.02) 0.121 0.78 (0.45, 1.36) 0 0.26 0.83, 1.03 No association 
Grigoriadis, 2013  Cardiovascular 
malformations 
SSRI during first 





RR 1.36 (1.08, 1.71) 0.009 0.50 (0.06, 4.43) 31 0.34 0.81, 2.29 Weak 
Wu, 2012 Fracture risk SSRI exposure in 
general population of 





RR 1.72 (1.51, 1.95) 4.3x10-18 1.40 (1.34, 1.46) 91 0.06 1.12, 2.61 Highly 
suggestive 
Eom, 2012 Fracture risk SSRI exposure in 
general population of 









Loke, 2008 Upper 
gastrointestinal 
bleeding 
SSRIs (Patients with 
various disorders 








OR  2.35 (1.44, 3.85) 0.001 3.60 (2.70, 4.70) 96 0.43 0.23, 24.66 Weak 
Loke, 2008 Upper 
gastrointestinal 
bleeding 
SSRIs + NSAIDs  
(Patients with 
various disorders 








OR  6.33 (3.39,11.81)  6.5x10-9 12.20 (7.10, 19.50)   91 0.16 0.36, 111.44 Weak 
Bar-Oz, 2007  Cardiovascular 
malformations 








OR 1.79 (1.27, 2.53) 0.001 2.16 (1.25, 3.72) 0 0.79 1.10, 2.92 Weak 
Bar-Oz, 2007  Major 
malformations 
First 







OR  1.33 (1.03, 1.71) 0.03 1.83 (0.59, 5.64) 23 0.98 0.78, 2.26 Weak 






9 Cohort OR 1.40 (0.86, 2.33) 0.17 1.12 (0.08, 17.78) 0 0.87 0.76, 2.34 No association 






8 Cohort OR 1.18 (0.36, 3.89) 0.78  3.40 (0.21, 251.89) 0 0.43 0.25, 5.65 No association 






2 Cohort OR 0.93 (0.13, 6.60) 0.94 0.39 (0.22, 0.71) 0 NA NA No association 






5 Cohort OR  1.70 (1.26, 2.30) 0,001  2.06 (0.86, 5.17) 0 0.92 1.04, 2.78 Weak 
Healy, 2016 Autistic Spectrum  
or 





5 Case-control OR 1.99 (1.67, 2.36) 5.0x10-15 2.3 (1.23, 2.74) 0 0.57 1.50, 2.63 Weak 






OR 0.93 (0.65, 1.33) 0.672 1.29 (0.89, 1.87) 98 0.400 0.24, 3.60 No association 
McDonagh, 2014  Preterm birth Antidepressant 
during pregnancy  




OR  1.84 (0.79, 4.27) 0.155 1.73 (0.63, 4.58) 0 NA NA No association 








OR 1.58 (1.31,1.92) 2.0x10-5 1.38 (0.91, 2.10) 14 0.22 1.12, 2.23 Weak  
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OR 1.44 (1.37, 1.51)  6.0x10-50 1.44 (1.37, 1.51) 0 0.50 1.30, 1.61 Suggestive 
Huybrechts, 2014 Preterm birth Antidepressant 
during pregnancy 





OR 1.57 (1.41, 1.75) 3.x10-16 1.21 (0.67, 2.21) 19 0.00 1.26, 1.97 Suggestive 
Myles, 2013 Major  
malformations 
Fluoxetine during 





OR 1.14 (1.01, 1.30) 0.04 0.79 (0.56, 1.12) 32 0.58 0.76, 1.78 Weak 
Myles, 2013 Major  
malformations 
Paroxetine during 





OR 1.29 (1.11, 1.49) 0.001 1.00 (0.06, 16.85) 0 0.28 1.07, 1.55 Weak 
Myles, 2013 Major  
malformations 
Sertraline during 





OR 1.01 (0.88, 1.17) 0.88 0.62 (0.09, 4.00) 0 0.84 0.83, 1.24 No association 
Myles, 2013 Major  
malformations 






OR 1.06 (0.93, 1.21) 0.37 0.97 (0.81, 1.16) 0 0.59 0.88, 1.28 No association 
Myles, 2013 Cardiovascular 
malformations 
Fluoxetine  during 





OR 1.21 (0.99, 1.48) 0.07 0.77 (0.19, 3.11) 0 0.57 0.91, 1.61 No association 
Myles, 2013 Cardiovascular 
malformations 
Paroxetine during 





OR 1.44 (1.16, 1.79) 0.001 0.88 (0.21, 0.80) 6 0.88 1.03, 2.01 Weak 
Myles, 2013 Cardiovascular 
malformations 
Sertraline during 





OR  0.97 (0.64, 1.48)  0.90 0.65 (0.34, 1.25) 63 0.34 0.25, 3.87 No association 
Myles, 2013 Minor  
malformations 






OR 1.18 (0.84, 1.66) 0.34 0.62 (0.20, 1.92) 32 0.33 0.54, 2.59 No association 
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19 Cohort OR 1.17 (0.44, 3.09) 0.75 2.17 (0.92, 4.35) 98 0.41 0.02, 70.99 No association 






6 Cohort OR 1.35 (0.61, 3.00) 0.45 1.06 (0.70, 1.56) 89 0.78 0.10, 18.31 No association 




RR 1.29 (1.09, 1.54) 0.00 1.41 (1.37, 1.45) 73 0.47 0.81, 2.07 Weak 






RR 1.33 (0.86, 2.06) 0.20 1.00 (0.61, 1.63) 38 0.43 0.02, 85.96 No association 




RR 1.15 (0.98, 1.36) 0.09 1.10 (0.88, 1.37) 0 0.37 0.39, 3.37 No association 




6 Cohort RR 2.06 (1.40, 3.03) 2.3x10-4 2.60 (1.84, 3.68) 58 0.79 0.67, 6.28 Suggestive 






7 Cohort RR 1.15 (0.97, 1.36) 0.11 1.20 (1.04, 1.39) 30 0.11 0.78, 1.68 No association 




367/ 5780 3 Cohort  RR 1.46 (0.99, 2.16) 0.06 1.48 (0.83, 2.66) 0 0.75 0.12, 18.58 No association 






12 Cohort RR 1.18 (1.08,1.29 3.5x10-4 1.25 (1.10, 1.42) 0 0.49 1.06, 1.30 Suggestive 






12 Cohort RR  1.36 (1.17, 1.59) 9.0x10-5 1.34 (1.10, 1.63) 23 0.12 0.99, 1.87 Suggestive 








RR 1.53 (1.31, 1.78) 4.0x10-8 2.17 (1.20, 3.93) 33 0.82 1.07, 2.19 Convincing 









RR 1.38 (1.13, 1.69) 0.002 0.97 (0.54, 1.73) 53 0.74 0.80, 2.23 Weak 










RR 1.38 (1.14, 1.69) 0.001 1.50 (1.01, 2.22) 25 0.96 0.86, 2.24 Weak 
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during pregnancy  
NR/ 
NR 
3 Sibling study 
design 
RR 0.88 (0.70, 1.12) 0.296 0.70  (0.37, 1.31) 0 0.08 0.19, 4.00 No association 






9 Cohort RR 1.11 (1.03, 1.19) 0.004 1.13 (1.06, 1.20) 38 0.83 0.94, 1.31 Weak 






18 Cohort RR 1.24 (1.11, 1.37) 6.2x10-5 1.03 (0.86, 1.24) 59 0.45 0.89, 1.71 Weak 
TCAs– tricyclic antidepressants, SSRI – selective serotonin reuptake inhibitors, I2 –heterogeneity, CI – confidence interval, OR – odds ratio, RR – relative risk, HR– hazard ratio, 















Boukhris, 2017 Gender, birth year, maternal age, maternal education level, recipient of social assistance, area of residence, maternal 
psychiatric disorders in the year prior to or during pregnancy (depression/anxiety, other psychiatric disorders), 
maternal comorbidities (gestational diabetes, gestational hypertension), maternal history of ADHD 
 Laugesen, 2013 Gender of the child, calendar time at birth, birth order, maternal age at birth, maternal smoking status, maternal 
psychiatric diagnoses, paternal psychiatric diagnoses, maternal diseases during pregnancy (infections, epilepsy) and 
maternal anxiolytics/ hypnotics/sedatives use during pregnancy 
 Malm, 2016 Sex; socioeconomic status; smoking during pregnancy; neonatal care unit; maternal history of other psychiatric 
diagnosis; maternal history of substance abuse; paternal history of psychiatric diagnosis; parental death 
 Man, 2017 Maternal age at delivery, infant’s sex, birth year, birth hospital, parity, maternal underlying medical conditions before 
delivery (pre-existing diabetes, epilepsy, gestational diabetes, psychiatric conditions, hypertension), use of other 
psychotropic drugs (antipsychotics, British National Formulary chapter 4.2.1, 4.2.2), and socioeconomic status. 
 Sujan, 2017 Parity; year of birth; country of birth; age at childbearing; highest level of completed education; history of any 
criminal conviction; history of severe psychiatric illnesses (inpatient diagnosis of ICD-8, ICD-9, or ICD-10 
schizophrenia, bipolar disorder, or other non-drug-induced psychoses); and history of any suicide attempts. 
 Clements, 2015 Gender, race, birth year, insurance type, median income tertile, past history of maternal depression 
 Figueroa, 2010 Maternal age group, gender of the child, urban or rural metropolitan statistical area, year of birth, age at last claim 
and at end of eligibility, maternal and paternal mental health diagnoses, the presence or absence of maternal mental 
health-related visits by period of time, the use of other psychotropics during pregnancy, and perinatal complications 
Fu, 2018 
Cataract risk 
Becker, 2017 Calendar time (same index date), age, sex, general practice, and number of years of active history in the CPRD 
before the index date, BMI, smoking, diabetes, hypertension, and systemic steroids 
 Chou, 2017 Age, sex, index date, patient’s demographics, mental illness characteristics, propensity score derived from comorbid 
conditions, and concomitant medications 
 Klein, 2001 Age and gender 
Morales, 2018  
Autism pre-pregnancy 
exposure 
Boukhris, 2016 Gender, year of birth, maternal age, marital status, living alone, education, social assistance or care, maternal 
psychiatric history, paternal psychiatric history, maternal physical history, paternal physical history 
 Brown, 2017 Gender, gestational age at delivery, maternal age, maternal psychiatric history, maternal physical history, pre-
pregnancy related/delivery, severity of depression, parity, drugs other than antidepressants 
 Castro, 2016 Gender, year of birth, gestational age at delivery, maternal age, education, maternal psychiatric history, maternal 
physical history, severity of depression, parity, insurance type ethnicity or country of origin, maternal income                
43 
 
 Clements, 2015 Gender, year of birth, birth weight, gestational age at delivery, maternal age, education, maternal psychiatric history, 
maternal physical history, pre-pregnancy related/delivery, severity of depression, parity, insurance type ethnicity or 
country of origin   
 Croen, 2011 Gender, year of birth, birth weight, gestational age at delivery, maternal age, education, maternal psychiatric history, 
parity, ethnicity or country of origin   
 Hviid, 2013 Gender, year of birth, gestational age at delivery, maternal age, education, maternal psychiatric history, smoking 
status, parity, ethnicity or country of origin residence, employment status 
 Sujan, 2017 Year of birth, maternal age, education, maternal psychiatric history, parity, ethnicity or country of origin, 
Laporte, 2017  
Severe bleeding at any 
site 
de Abajo 1999 UGIB history, smoking status, current use of NSAID, AC, corticosteroids, aspirin 
 de Abajo 2000 Hypertension, migraine, asthma or COPD, smoking status, BMI, current use of NSAIDs 
 Bak 2002 Age, sex, hypertension, diabetes, smoking status, AC, antiarrhythmics, antianginal drugs 
 Meijier 2004 Bleeding history, NSAIDs, AC, glucocorticoids, estrogens, progesterones, histamine blockers, PPIs, antidiabetic 
agents 
 Kurdyak 2005 UGIB history, current use of aspirin, NSAID, glucocorticoid, PPIs, H2 reuptake inhibitors 
 Tata 2005 NR 
 Helin-Salmivaara 2007 Histamine-2 receptor antagonist, plain misoprostol, PPIs, warfarin, clopidogrel or inhaled glucocorticoid and 
tramadol, hospitalisation for arthroplasty, hypertension, angina pectoris, cardiac insufficiency, diabetes mellitus, 
rheumatoid arthritis, asthma 
 Kharof 2007 NR 
 Vonbach 2007 Glucocorticoids, NSAIDs, AC, SSRIs, TAIs, PPIs, hypertensive disease 
 Ziegelstein 2007 NR 
 de Abajo 2008 Age, sex, calendar year, smoking status, alcohol intake, history of GI disorder, NSAIDs, systemic corticosteroids, 
warfarin, low-dose aspirin, antiplatelet drug 
 Lewis 2008 Age, sex, race, alcohol consumption, history of ulcer disease, hypertension, PPI use, H2RA use, ASA dose and 
NSAID dose 
 Opatrny 2008 Age, sex, BMI, blood pressure, smoking status, comorbid conditions, warfarin, clopidogrel, antidepressant 
 Salkeld 2008 Previous PPH, multiple pregnancy, prolonged labor, abnormalities of the forces of labor, obstructed labor, perineal 
laceration or other gynecologic laceration, other obstetric trauma, placenta previa, placental abruption, and 
hypertensive disorders of pregnancy 
 Schalekamp 2008 NR 
 Vidal 2008 History of peptic ulcer, dyspepsia, UGIB, diabetes mellitus, smoking habit, alcohol consumption and use of antacids, 
PPIs, sucrafalte, nitrates, systemic NSAIDs, topical NSAIDs, analgesics, antiplatelet drugs, dihidropyridine calcium 
antagonists and statin 
 Barbui 2009 Age, gender, use of antianemic preparations, use of drugs for peptic ulcer 
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 Chen 2009 Use of aspirin, AC, risperidone, anxiety, alcohol abuse, substance abuse, hypertension, diabetes, 
hypercholesterolemia, cardiac diseases 
 Dall 2009 Age, gender, calendar year, low dose aspirin, PPIs, NSAIDs, alcohol abuse, cerebral ischemia, stroke, warfarin, 
clopidogrel, dipyridamol, steroids, helicobacter eradication, peptic ulcer, UGIB, cirrhosis 
 Targownik 2009 Cardiovascular disease, respiratory disease, hepatic disease, renal disease, active malignancy, alcohol abuse, 
depression, schizophrenia, acute hospitalisation, upper endoscopy, H2-receptor antagonists, warfarin, clopidogrel, 
systemic corticosteroids, tricyclic antidepressants 
 Carvajal 2011 Alcohol and caffeine consumption, past history of GI disorders, family history of GI bleeding, osteoarthritis, number 
of medicines taken and use of NSAIDs, salicylates, PPIs, H2 antihistamines, antacids, antiplatelet agents and AC 
 Douglas 2011 Smoking, alcohol, BMI, prior history of transient ischemic attack or other stroke, hypertension, diabetes, NSAID use, 
aspirin use, clopidogrel or dipyridamole use, year of first prescription, observation time 
 Verdel 2011 NSAIDs, oral glucocorticoids, PPI, platelet aggregation inhibitors 
 de Abajo 2013 Age, gender, calendar year, smoking, peptic ulcer history, number of GP visits in the year prior to index date and 
concomitant use of other medications 
 Andreasen 2006 Age, sex, preoperative use of platelet inhibitors, NSAIDs, oral anticoagulant, place of surgery, use of extracorporal 
circulation, concomitant valve surgery, Charlson comorbidity index 
 Hauta-Aho 2009 Age, sex, study ward, PPI and oral glucocorticoid medications 
 Kim 2009 NR 
 Gärtner 2010 Age 
 Tully 2012 Propensity score (including age, sex, urgency of surgery, previous myocardial infarction, respiratory disease, left 
ventricular ejection fraction, diabetes mellitus, renal disease, peripheral vascular disease, cerebrovascular disease, 
cardiogenic shock, heart failure, hypertension, smoking and OPCAB procedure, statin, antiplatelet, anticoagulants) 
 Basile 2013 Age, body weight, surgery type 
 Mortensen 2013 Propensity-matched analysis (among 5837 users and 30338 non-users) and use of other drugs during follow-up (non-
SSRI, other antidepressant, blood pressure lowering drugs, platelet inhibitors, VKA, statins) 
 Seitz 2013 Age, sex, Charlson score, number of medications, residence (long-term care or community) 
 Quinn 2013 Time varying ATRIA bleeding risk score, INR value 
Jiang, 2016 
Postpartum hemorrhage 
Salkeld  2008 Previous postpartum hemorrhage, multiple pregnancy, prolonged labor, abnormalities of the forces of labor, 
obstructed labor, perineal laceration or other gynecologic laceration, other obstetric trauma, placenta previa, placental 
abruption, and hypertensive disorders of pregnancy 
 Palmsten 2013 Delivery year, age, race, multiple pregnancy, diabetes, coagulopathy, number of outpatient mood/anxiety disorder 
diagnoses, number of inpatient mood/anxiety disorder diagnoses, psychotic disorder, other mental health disorder, 
pain indication, sleep disorder, anticonvulsant dispensing, benzodiazepine dispensing, aspirin dispensing, heparin 
dispensing, low molecular weight heparin dispensing, warfarin dispensing, and number of outpatient visits and days 
in hospital during baseline. 
 Lindqvist  2014 Maternal age, parity, BMI, educational level, smoking, coagulation defects, history of previous abortion/miscarriage, 
placental abruption, placenta previa, and maternal depressive symptoms. 
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 Lupattelli  2014 Maternal age, marital status, BMI, smoking, placenta previa, bleeding episode in first trimester, and depressive 
symptoms. 
 Grzeskowiak 2015 Delivery year, age, socio-economic status, race, multiple pregnancy, parity, smoking status, alcohol or substance 
abuse during pregnancy, coagulation defects, asthma, diabetes, hypertension, previous caesarean section, and use of 
other psychotropic medications 
 Joseph 2015 Social assistance, residence urban, previous caesarean, multi-foetal pregnancy, placenta previa/ abruption, 
polyhydramnios, prolonged labour, preeclampsia/eclampsia, epidural analgesia, labour induction, uterine rupture, 
cervical laceration, caesarean delivery, perineal laceration, vaginal laceration, chorioamnionitis. 
 Hanley 2016 Year of birth, maternal age, parity, preterm birth, multifetal pregnancy, diabetes (both gestational and pre-existing), 
coagulopathy, smoking during pregnancy, blood thinner use in the month before delivery, anxiolytic use in the month 
before delivery, antipsychotic use in the month before delivery, a diagnosis of mood disorder, any psychiatric visits, 
or any psychiatric hospitalization in the 5 months before delivery. 




de Abajo  1999 UGIB history, smoking status, current use of NSAID, AC, corticosteroids, aspirin 
 Helin-Salmivaara  2007 Histamine-2 receptor antagonist, plain misoprostol, PPIs, warfarin, clopidogrel or inhaled glucocorticoid and 
tramadol, hospitalisation for arthroplasty, hypertension, angina pectoris, cardiac insufficiency, diabetes mellitus, 
rheumatoid arthritis, asthma 
 de Abajo 2008 Age, sex, calendar year, smoking status, alcohol intake, history of GI disorder, NSAIDs, systemic corticosteroids, 
warfarin, low-dose aspirin, antiplatelet drug 
 Schalekamp 2008 NR 
 Opatrny 2008 Age, sex, BMI, blood pressure, smoking status, comorbid conditions, warfarin, clopidogrel, antidepressant 
 Lewis  2008 Age, sex, race, alcohol consumption, history of ulcer disease, hypertension, PPI use, H2RA use, ASA dose and 
NSAID dose 
 Vidal  2008 History of peptic ulcer, dyspepsia, UGIB, diabetes mellitus, smoking habit, alcohol consumption and use of antacids, 
PPIs, sucrafalte, nitrates, systemic NSAIDs, topical NSAIDs, analgesics, antiplatelet drugs, dihidropyridine calcium 
antagonists and statin 
 Barbui  2009 Age, gender, use of antianemic preparations, use of drugs for peptic ulcer 
 Targownik  2009 Cardiovascular disease, respiratory disease, hepatic disease, renal disease, active malignancy, alcohol abuse, 
depression, schizophrenia, acute hospitalisation, upper endoscopy, H2-receptor antagonists, warfarin, clopidogrel, 
systemic corticosteroids, tricyclic antidepressants 
 Dall 2009 Age, gender, calendar year, low dose aspirin, PPIs, NSAIDs, alcohol abuse, cerebral ischemia, stroke, warfarin, 
clopidogrel, dipyridamol, steroids, helicobacter eradication, peptic ulcer, UGIB, cirrhosis 
 Carvajal 2011 Alcohol and caffeine consumption, past history of GI disorders, family history of GI bleeding, osteoarthritis, number 
of medicine taken and use of NSAIDs, salicylates, PPIs, H2 antihistamines, antacids, antiplatelet agents and AC 
 Verdel 2011 NSAIDs, oral glucocorticoids, PPI, platelet aggregation inhibitors 
 de Abajo 2013 Age, gender, calendar year, smoking, peptic ulcer history, number of GP visits in the year prior to index date and 
concomitant use of others medications 
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 Wang 2014 Concurrent drug use 
 Huang  2011 Age, concurrent drug use 
Huang, 2014 
Preterm birth 
Nordeng 2012 Depression 
 Yonkers 2012 Depression 
 Latendresse 2011 Depression 
 Lewis 2010 Depression 
 Lennestal 2007 NR 
 Suri 2007 Depression 
Wu, 2013 
Fracture risk, TCAs 
Ensrud 2003 Age, health status, use of ≥1 medication, walking for exercise, functional impairment, fall in previous year, cognitive 
function, weight change, gait speed, inability to rise from chair, femoral neck BMD 
 Lewis 2007 Age, BMD 
 Ziere 2008 Age, sex, depression during follow‐up period, disability category, lower‐limb disability 
 Diem 2011 Age, health status, IADL, ability to rise from chair, m‐MMSE, smoking, alcohol use, estrogen use, bisphosphonate 
use, benzodiazepine use, thiazide use, PPI use, oral steroid use, weight, GDS score, walks for exercise, history of 
prior fracture, total‐hip BMD and history of falls in previous year 
 Coupland 2011 Age, sex, depression, deprivation, smoking status, comorbidities (ischemic heart disease, DM, HTN, stroke, cancer, 
dementia, epilepsy or seizures, PD, hypothyroidism, OCD) and use of other drugs (eg, statins, NSAIDs, 
antipsychotics, lithium, aspirin, anti‐HTN drugs, anticonvulsants, hypnotics, anxiolytics) 
 Ray 1987 Sex, race, age, index year, and home status, diagnosis of dementia 
 Ray  1991 Age, sex, calendar year, nursing home residence on index date, and for hospitalization and use of specific 
medications (narcotic analgesics, anti‐HTN, and other cardiovascular drugs) in year preceding index date 
 Liu 1998 Age, sex, comorbidity (eg, depression, dementia, osteoporosis), previous drug exposure (eg, sedative, tranquilizer, 
cardiac drug, anti‐PD agent, thyroid‐replacement drug, anticonvulsant, insulin, glucocorticoid, estrogen, etidronate) 
 Hubbard 2003 Age, sex, general practice, duration of available GPRD data, history of falls, and history of prescriptions for 
hypnotics and antipsychotics 
 Vestergaard 2006 Age, sex, psychiatric comorbidity (eg, manic depression, schizophrenia, alcoholism, eating disorder); medication use 
(eg, anxiolytic, sedative, neuroleptic, corticosteroid, antiepileptic, cardiovascular agent, lithium); hospital stay; prior 
fracture; income; working, educational, and residential status; Charlson index 
 Van den Brand Age, sex, geographical region, other antidepressant, use of benzodiazepine, antipsychotic, lithium, anti‐PD agent, 
anticonvulsant, oral‐inhaled corticosteroid, bronchodilator, HRT, antiarrhythmic, thiazide diuretic, β‐blocker, 
opioids, anticonvulsants, DM drug, ≥2 dispensings of an NSAID, DMARDs, metoclopramide hydrochloride; history 
of malignant neoplasm, mental disorder, cerebrovascular disease, obstructive airway disease, or IBD 
 Verdel 2010 Age; sex; geographical area; calendar time; cancer; cardiovascular disease; cerebrovascular disease; IBD; mental 
disorder; obstructive airway disease; use of antidiabetic, antiepileptic, anti‐PD drug, antipsychotic, benzodiazepine, 




Apgar score at 5 minutes 
Simon et al., 2002 maternal age, year of delivery, lifetime number of antidepressant prescriptions filled or refilled, lifetime history of 
outpatient psychiatric treatment, lifetime history of inpatient psychiatric treatment, tobacco use, other substance use, 
race, number of prior births 
 Laine et al., 2003 maternal age, gravidity, parity, gestational age, time and mode of delivery 
 Zeskind & Stephens, 2004 maternal age (±2 yrs), maternal cigarette use, low socioeconomic status,  
 Pearson et al., 2007 age (±5 years), parity, tobacco use, marital 
status 
 Calderon-Margalit et al., 2009 maternal age, race, marital status, education, smoking during pregnancy, preeclampsia, parity, singleton pregnancy 
 Lund et al., 2009 maternal age, BMI, smoking, a previous pregnancy with prematurity, gestational age, previous birth of a low‐birth‐
weight infant, parity, and coffee and alcohol intake 
 Wisner et al., 2009 maternal age, race 
 Reis et al., 2010 year of birth, maternal age, parity, smoking, body mass index (BMI) 
Oderda, 2012 
Hip fracture  
van den Brand (2009) Age sex, medications, comorbidities 
 Chang (2008) Age, sex 
 Ensrud (2003) Age, debilitation, gait speed, femoral neck, bone density 
 Hubbard (2003) History of falls, medications 
 Wang (2001) Age, sex, race, medications, debilitation 
 Jacqmin-Gadda (1998) Age, sex, residence 
 Guo (1998) Comorbidities, medications 
 Liu (1998) Comorbidities, medications 
 Johansson (1996) Sex, comorbidities 
 Lichtenstein (1994) Age, sex, comorbidities 
 Cumming (1993) Age, sex, residence 
 Jensen (1991) Age, sex, debilitation, medications 
 Ray (1991) Age, sex, debilitation, medications 
 Ray (1987) Age, sex, race, residence 
Barbui, 2009 
Suicide attempt and 
completion 
Olfson 2006 White population, median income, number of per capita physicians pediatricians, child psychiatrists and psychiatrists  
 Olfson 2006 Age, sex, race, substance use disorder, recent suicide attempt, treatment with antipsychotic anxiolytic, hypnotic, 
stimulant and mood stabilizing drugs 
 Sondergard 2007 Age, sex, and socioeconomic classification 
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 Tiihonen 2006 Age, sex, geographical location, number of suicide attempts before the index hospitalization, number of suicide 
attempts during follow/up, use of multiple antidepressants and number of purchased antidepressants during the 
previous year 
 Gibbons 2007 No 
 Valuck 2004 Propensity score and calendar year 
Khanassov, 2018 
Fracture risk; SSRIs 
van den Brand, 2009 Age, sex, geographical region, other than SSRIs antidepressants, benzodiazepines, antipsychotics, lithium, anti‐
Parkinson drugs, anticonvulsants, corticosteroids, hormone‐replacement therapy, disease‐modifying antirheumatic 
drugs, nonsteroidal antiinflammatory drugs, antiarrhythmic, thiazide diuretics, beta‐blockers, opiates, 
metoclopramide, antidiabetic drugs; history of hospitalization  
Verdel, 2010 Age, sex, geographical region, calendar time, other than SSRIs antidepressants, benzodiazepines, antipsychotics, 
lithium, anti‐Parkinson drugs, anticonvulsants, corticosteroids, hormone‐replacement therapy, disease‐modifying 
antirheumatic drugs, nonsteroidal antiinflammatory drugs, antiarrhythmic, thiazide diuretics, beta‐blockers, opiates, 
metoclopramide, antidiabetic drugs, thyroid hormones; history of hospitalization 
 Vestergaard, 2006 Age, sex, psychiatric comorbidity (eg, schizophrenia, alcoholism), medication use such as anxiolytic, sedative, 
neuroleptic, corticosteroid, antiepileptic, lithium, hospitalization, prior fracture, income, working status, education, 
residence, Charlson index 
 Bolton, 2008 Age, sex, ethnicity, income, residence, comorbidity index of the John Hopkins Ambulatory Care Group system 
(diabetes, ischemic heart disease, myocardial infarction, hypertension, epilepsy, rheumatoid arthritis, organ 
transplantation, COPD, home care use, depression, substance abuse, dementia, schizophrenia), medication use such 
as anticonvulsants, diuretics, anticoagulant, thyroid hormone 
 Liu, 1998 Age, sex, comorbidities (depression, dementia and other), medications such as sedatives, tranquillizers, cardiac 
agents, anti‐Parkinson drugs, thyroid hormones, anticonvulsants, diabetic agents, corticosteroids, estrogens, 
etidronate; different exposure categories and doses of antidepressant 
 Abrahamsen, 2009 Age, previous fracture, modified Charlson comorbidity index, groups of medications 
 Wang, 2016 Age, sex, hypertension, diabetes, osteoporosis, history of falls, cardiac diseases, chronic obstructive pulmonary 
disease, urinary incontinence, Parkinson disease, chronic mental disorders, dementia, depression, liver disease, 
peripheral vascular disease, cerebrovascular disease, arthritis, chronic kidney diseases, glaucoma; use of medications 
(opiates, nonopioid analgesics, antipsychotics, anxiolytics, sedatives, corticosteroids, hormone replacement therapy, 
antiepileptics, tricyclics 
 Rabenda, 2012 Lumbar spine, femoral neck and total hip BMD, depression, history of vertebral/ nonvertebral fracture, 
benzodiazepine use, antihypertensive and antiarrhythmic drugs 
 Spangler, 2008 Age, BMD, height, weight, ethnicity, physical function, hormone replacement therapy, smoking, years since 
menopause, number of falls, previous fracture, use of analgesics, narcotics, cardiovascular diseases 
 Richards, 2007 Age, sex, education, study center, BMI, comorbidities based on modified Charlson index, self‐reported general 
health, prior smoking and alcohol intake, history of falls and fractures, calcium and vitamin D intake, dementia based 
on MMSE, depression, medication use such as bisphosphonates, antihypertensive, diuretics, corticosteroids, 
estrogens, benzodiazepines, anticonvulsants, antipsychotics, tricyclics, BMD 
 Lewis, 2007 Age, BMD 
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